Lists Of 100% Daily Online Dating Site In Usa

Posted on
Lists Of 100% Daily Online Dating Site In Usa Rating: 6,0/10 5528 votes
  • Italian Singles, Chat, Dating, Italian Men & Women
  • Affiliate Marketing Forum AffiliateFix
  • Affiliate Program Database - Warrior Forum
  • Dating Serial Numbers with a Letter Prefix - Savage Shooters
  • Cpamatica - your best affiliate network 2021
  • Adultsex Dating Sexdating, Sexchat, Swinger, Sexaftaler
  • Adult FriendFinder - The World's Largest Adult Dating and ...
  • STM Forum - The #1 Affiliate Marketing Forum
  • Affiliate Marketing Forum affLIFT
  • 17+ Hookup & Sex Dating Sites - Find Local Hookups & Get ...

Exclusive products and services available only at Warrior Forum Get great deals on Internet Marketing Products, Services, Trainings and other Offers at the world's largest Internet marketing marketplace ... Private Ad Network - Sweeps, Dating, Nutra, Downloads & More by PrivateCPA. PrivateCPA ... Affiliate Program Database Warriors For Hire ... Affiliate Marketing Forum AffiliateFix. The number one Affiliate and CPA marketing forum online. Affiliate Networks and more. Menu. Forums. New posts Search forums. ... Monetize Your Dating Traffic View this Deal. AdPlexity 30% OFF FOR LIFE! View this Deal. CPARK Digital Performance Marketplace View this Deal. Partner. Partner. A Friendly and ... Do you want to get laid? Are you searching for hookup sites? Find real girls looking for a sex date locally and fuck her tonight! Single or married, these are horny women looking for a sexual encounter or affair with men. Forget Tinder and find adult dating sites that work online! Sign up and find sex fast 100 % guaranteed! Affiliate marketing forum filled with over 50,000 affiliates and exclusive guides, case studies, and example affiliate marketing campaigns! How do you make cheeky agreement anonymously?. A swinger party is a party where there are a few printed laws to adhere to. Otherwise, there is the opportunity to grow sex in cross-section of relationships with such a party. While adult dating, you can find friends for adult dates, and get laid if you and your partners want to get it on! When you browse our sex personals, you'll immediately find there are many local adult matches for you, also looking for sex dating. Adult dates are likely to result in sex hookups, online sex friends or hot fuck friends. Italian Dating & Chat for Italian Singles. Welcome to one of the fastest growing Italian singles sites on the web. Italiano Singles is one of the best Italian dating sites that helps Italian singles like yourself meet your Italian soul mate. Italian personals features include Italian chat, photo galleries, informative profiles and much more.We encourage you to explore the site and browse ... STM Forum was launched late one night in January 2011 with the goal of providing case studies, guides, high quality information on a variety of topics and to act as a core networking hub for industry veterans.. 7 years later we are the authoritative forum on affiliate marketing and our reach continues to expand. We now provide higher education, host conferences and local networking events, and ... If you want to expand your business and look more professional, you need to join an affiliate network. Cpamatica helps affiliates, advertisers, media buyers, and agencies to get more customers and increase their profits. Cpamatica operates throughout North and South America, Europe, and Asia. All Savage firearms manufactured after December 1968 have a serial number which will have a letter prefix. This was done to clearly identify which firearms were manufactured after the Gun Control Act of 1968 went into effect. The graphic below outlines the starting and ending serial number for each year of production from 1969 thru the beginning of 2012 (the most recent we have data for).

The ten channels of digital marketing and how to apply in 2021

2021.12.23 19:09 ZestyBellsThe ten channels of digital marketing and how to apply in 2021

Hottest dating site in usa. The point is that with the help of online dating services people get a better chance to choose their perfect date and a few. Dating and chat, best dating sites in usa 2021Fed up with ghosting online dating dating site statistics other ways to say dating. Tiktok siblings or dating. Dating ocps muslim dating website usa. Celebs go dating season 9 episode 3 123movies. Upward dating bio white 100 percent usa. free site dating dating label in sites.

What Is Digital Marketing?
Digital marketing is a term defined to achieve your business objectives and goals using the online channels that include but are not limited to search engines, social media platforms, affiliate marketing, email marketing, content creation & advertising in order to educate, engage & market your product or service to potential buyers. Digital marketing now includes other forms of new digital channels such as mobile, digital TV, digital watches, and other digital and IoT-related products linked with the internet.
Just a decade ago, if a business wanted to reach out to target customers, they would promote using traditional marketing mediums such as TV, radio, print. Simply because that’s where the potential customers’ used to spend their time. However, as humans evolved our technology advanced giving rise to a digital revolution. To simply state, people started spending more time on online platforms such as Google, Facebook, Instagram, YouTube, etc to stay acquainted with news, entertainment, and commerce. Hence, today our lives run on a click.
Digital has become a part of our existence. From shopping apparel to groceries, furniture & getting laundry delivered everything is online. With this new shift, marketers did not waste any time and quickly adapted to use social media & other digital tools to push & pull the consumer which gave birth to Digital marketing.
  1. If you want to find some budget dating site but can't choose, then this article is what you need. Here you will find the best top free online dating sites.
  2. Online 100% free Dating Sites In Germany – The 6 greatest online dating services in Germany While many Germans communicate English, this preferred webpages is a german opportunity to brush up on your German techniques. Setting-up a english is not difficult. This programs seems to edarling most phony pages and fraudsters than other German.

No matter the size of your business, digital marketing is the most effective way to grow and achieve your goals which could vary from any of the following:
Top Objectives of Digital Marketing
  • Increase revenue
  • Build brand awareness
  • Market your product or service
  • Decrease cost
  • Improve efficiency
  • Increase productivity
  • High return on investment
  • Identify loyal customers
Apart from these business objectives, digital channels can be used effectively for:
  • Educating & engaging with potential users
  • Increase website traffic
  • Providing valuable information
  • Building trust
  • Customer reviews
  • Grow online community
    Top Ten Types of Digital Marketing
1 - Search Engine Optimisation (SEO)
2 - Search Engine Optimisation (PPC Paid Marketing)
3 - Affiliate Marketing
4 - Social Media / Influencer Marketing
5 - Display Advertising
6 - Email Marketing
7 - Content Marketing
8 - Mobile Marketing
9 - Pragmatic
10 - Remarketing
1 - Search Engine Optimisation (SEO)
Whoever controls the door to the Internet, controls the Internet. And now search engines have become the default entry point to the Internet. We start with a simple search by typing a few words into a search engine, often oblivious to exactly what happens behind the scenes. When we search in Google, for example, we are not actually searching the Internet; we are searching Google's index of the Internet, that is, the list of the sites that it has found online. So the challenge for effective search engine optimization (SEO) involves understanding how search engines work and how to play by their rules.
SEO statistics by Forbes cite Borrell Associates to emphasize that by 2020, businesses in the US will be spending as much as $80 billion on SEO services. This number is significantly higher than in 2016 and 2018 when businesses were spending $65.26 and $79.27 billion on search engine optimization, respectively.
The SEO Process
1. Goals. From the outset, it's important to be aware of the benefits of SEO. They will serve as key drivers as you navigate the development of your SEO strategy. You must decide upon and set up clear, realistic goals and targets for your SEO campaign. The benefits of spending time developing goals far outweigh the risks of walking the plank blindfolded into the competitive world of search marketing. Just one error could result in a six-month search engine penalization — with SEO, ignorance certainly is not bliss!
2. On-page optimization. This deals with the granular, technical optimization of the various elements on your website. It involves ensuring search engines can easily read, understand, crawl through, and navigate the pages of your site to index it correctly.
3. Off-page optimization. This refers to techniques used to influence website position in organic search results that cannot be managed by on-page optimization of your site. It's a long-term, iterative process focused on gaining website authority, as determined by what other websites say about you. To put it simply, it's about building a digital footprint and earning online credibility.
4. Analyze. This stage is very much a cyclical process. You're now looking at the data coming back, analyzing it, and deciding upon the adjustments needed going forward. This will help you tweak your goals accordingly as you implement additional goals and changes.
Top Five SEO Tools
  • Google Search Console Free Tool
  • ahref
  • Moz
  • SEMrush
  • Majestic
    2 - Search Engine Marketing (PPC - Pay Per Click Marketing)
Appearing in the number-one position of a SERP is no easy feat, but what if you were told that SEO was not the only way to achieve this mammoth accomplishment? Search marketing, in particular pay-per-click (PPC) advertising, is another lucrative option available to you. The difference between SEO and PPC, however, is in the name, you have got to pay for PPC! Have you ever noticed those three listings at the top of a SERP with a yellow ad icon beside them, almost unfairly pushing down organic search listings? Those are the product of PPC savvy digital marketers, reaping the benefits of high click-through rates (CTRs) by paying a little extra.
The Process
1. Set your goals. Before beginning and investing in your PPC journey, you first need to learn about the benefits PPC can bring to your business. With this knowledge, you can then define exactly what your goals will be and how to align KPIs with them.
2. Set up your account. In this stage, you will be guided step-by-step through every element involved in setting up your very own Google Ads account, from creating PPC campaigns to assigning budgets.
3. Manage your campaigns. This stage details what happens after your campaigns have been launched and how best to manage them. The finer details of the Ads interface will also be explored to help you discover the variety of options you can implement to yield a higher return on investment (ROI).
4. Analyze your results. The final stage in the PPC process is all about measuring your success through KPIs, tools, and reports. By using this data you will be able to better optimize your campaigns for the next iteration while considering the relevant data protection and privacy issues associated with PPC.
Top Five PPCAd Networks
  • Google Ads
  • Bing Ads (Microsoft)
  • Facebook Ads Manager
  • LinkedIn Ads
  • Twitter Ads
    3 - Affiliate Marketing
Affiliate marketing combines the value of personal sales and technology solutions offered by online marketing. To companies with a lower budget, it provides an opportunity to increase profits and raise awareness of its brand.
In today's marketing, we are recording condensed advertising information flow. Advertisement recipient perceives from all sides. Marketing communication follows the trend of the closest contact with the recipients. This is doubly true in online marketing. With social networks, people provide the most personal information that today's technology can process in their favor. It is still, however, communication between the company and customers. Affiliate marketing is when you get paid a commission for promoting products/services for other companies.
Entities in Affiliate Marketing
Many affiliate marketing experts claim that this type of affiliate marketing works on the relationship between two entities, namely:
1. Merchant = merchant, sponsor, who created the affiliate program.
2. The actual affiliate = intermediary, the person who accepts the conditions of the affiliate program and promotes the product on the internet.
With the growing popularity and effectiveness of affiliate marketing to the said two entities joined the third - the owner of the affiliate network. This entity monetizes its position in this relationship by providing space to create affiliate programs for merchants. In the hierarchy of these entities, it is going to the highest point.
For the proper understanding of the financial flow of commissions, it is necessary to explain theoretically and define the individual entities.
Affiliate Network is a central hub tech and affiliate campaign management company on which takes place and runs affiliate programs that are generated by merchants. Affiliate Network brings together not only merchants but affiliates themselves as well. The value of an affiliate network is expressed by the number of active affiliate programs and the number of available affiliates. Some networks require a fee for access to the network. Other work on the principle of sales commission. Apart from the space for the creation program, they offer affiliate know-how as well. Networks are able to develop a detailed analysis of the target audience, how to communicate or make judgments on the affinity of the product for affiliate marketing.
Merchant is an eCommerce store that enters into affiliate networks in order to set up an affiliate program, increase profits and expand its product among Internet users at a relatively low cost. The merchant, therefore, offers its products through an affiliate program. He creates the conditions under which the affiliate receives a commission for each sale. Affiliate must then perform some type of action. This is usually about the sale, but there are programs that have a commission for registration, for filling in the form, and so on.
An affiliate is a person who can register to a particular affiliate program and promote the product in the online environment. The forms of promotion are diverse, but it consists mostly of banners and simple text ads. Every registered affiliate acquires its special link - a referral link, which becomes the identification in the system, with which the system can detect and record the activity of the affiliate.
The Benefits of Affiliate Marketing
  1. You can make a lot of money without lots of effort or extraordinary skills.
  2. You can make money while you sleep. Once you have a profitable campaign it can make money for you 24/7. You can even build employees and systems to take over everything.
  3. It’s simple to get started. All you need is a computer, internet, and some money to spend on traffic. You don’t have to hire employees or rent office space.
  4. There are no commitments or contracts. Don’t want to promote the offer anymore? Then stop. Want to go on vacation for 3 months? You can pause the campaign and go.
  5. It’s the best direct marketing training in the world. Many people use affiliate marketing as a stepping stone towards new opportunities. Affiliate marketing is business training on steroids.
The role of SaaS solutions in Affiliate Marketing
The aim of SaaS solutions such as RevGlue.com in affiliate marketing is to make affiliate marketing simple with a unique set of interactive tools, structured contents, and dynamic modules. These SaaS tools and contents are offered on a monthly subscription of revenue share basis to publishers to help them monetize their current affiliate websites, mobile applications or create new websites within minutes.
Top Affiliate Networks in the UK
  • Awin
  • CJ
  • TradeDoubler
  • TradeTracker
  • Webgains
  • Impact
  • Paid On Results
  • Rakuten
4 - Digital Display Advertising
Do you know those ads that follow you around the Internet? The ones that somehow know exactly what you have been searching for? Your computer is not psychic, you are simply experiencing remarketing, one of the tools of digital display advertising (DDA). As a digital marketer, you can create online ads just as you would for an offline campaign. These online ads (or display banners) contain copy, logos, images, maps, and video, anything that will hook users as they browse. Then you can call on certain publishers to pick the most relevant websites, social media channels, and devices for your ads to appear on. You learned that SEO is all about driving traffic to your site. Just as you should optimize your site so that it shows higher in search results, you should also optimize the ads that direct users to it by including a hyperlinked call to action, for example.
The Process
1. Define. This stage starts by helping you to identify and segment your customers based on demographics like age, location, and interests. You will learn how to find the right publisher for your ads and how to set display campaign objectives in line with your overall goals.
2. Format. This stage will introduce a range of creative ad formats, among which you can choose the most appropriate, according to your target audience and budget. Once you have looked at formats, you will learn about the media channels available to you and how you can create compelling ad copy across these channels.
3. Configure. You can maximize your campaign's potential by using targeting tools like Google Display Planner and assigning KPIs to help you track your campaign on an ongoing basis. Once you go live, you can't hide from the eyes of the public so it is best to iron out any bumps early on.
4. Analyze. The final stage is when you measure the success of your campaign using analytics. Then you can enhance and optimize your ads as necessary before getting ready to relaunch.
Top Five Display Advertising Ad Networks
  • Google AdSense
  • Facebook Audience Network Ads
  • Apple Advertising
  • Yahoo / Bing Network
  • Taboola
5 - Email Marketing
In a constantly evolving digital landscape, tools and platforms come and go. An email has remained a steadfast and dependable channel with 3.2 billion email accounts worldwide. That's three times more than the number of Facebook and Twitter accounts combined, and if optimized correctly, an email marketing campaign can be all-powerful, driving better returns on investment and higher levels of engagement. The fact that you can dispense with printing flyers, save trees, and be an email marketing pro? Well, those are just added bonuses!
The Process
1. Data. The first step in any email marketing campaign should always be the creation of a subscriber list. This is a compilation of email contacts who have consented to receive your communications (they've opted in). You can create as many lists as you need in order to segment your subscribers so that you can target them with relevant, personalized content that they will actually care about.
2. Design. This step involves deciding which content you should include in your email and the design principles you must follow, to ensure that your email ends up in a subscriber's inbox, ready to engage and excite them.
3. Delivery. This step is all about the delivery of your marketing emails. You will learn how they are managed through an email service provider (ESP), which facilitates everything from email style and layout to scheduling. Step 3 covers what happens to an email after it has been sent and delivered. You will learn how to utilize testing to decide what your email should look like and when you should send it to guarantee the best possible open rates.
4. Discovery. Analysis and reporting are fundamental when revising and refining your digital practices. Leveraging analytics tools will allow you to track every cent spent on your email marketing and let you track open rates, total opens, and unique opens. You will be able to track ROI through CTRs, unsubscribes, and bounce rates. Analytics tools are a gateway to highly detailed, clinical data that will enable you to tailor your email marketing strategy, taking into account both your successes and failures.
Top Email Delivery Tools
  • Hubspot
  • GetResponse
  • Sender
  • MailChimp
  • Sendblue
6 - Social Media Marketing
Find me on Facebook. Follow me on Twitter. Check out my blog. Ten years ago these phrases meant nothing, yet now they are part of everyday speech. More and more people are connecting through social media to stay in touch with friends, to date, or to interact with brands and businesses. Which is great news for digital marketers like you. This is no time to be a wallflower. Because in order to survive and thrive, you will need to be active on the main platforms, competing in an online popularity contest with other companies. SMM is a huge topic and the most important digital marketing type.
Media Types: Earned, Owned, and Paid
Before getting into how you can promote yourself on social media, let's look at the options that are available. You can choose to post content through the following media types:
Earned media is free publicity, generated by fans and customers in response to content they like (your kudos for making them happy).
Owned media includes communications that a brand creates and controls via its own platform (you blow your own trumpet).
Paid media is any paid activity that drives traffic to owned media properties (you pay up for the shout-out).
Whatever option you choose, remember that there will be hidden costs involved. An engaging profile requires a great copy, multimedia assets like photos and videos (which you may want to take yourself), and a solid strategy. And since there is no point in having the world's greatest profile if no one knows you exist, you will have to fork out for some kind of advertising to reach socially tuned-in audiences. Finding and training the right staff, compiling digital assets, and advertising your business takes time and money—so bear that in mind when setting out your short- and long-term goals.
Top Social Media Marketing Tools
  • SproutSocial
  • Falcon
  • Loomly
  • eclincher
  • Crowdcontrol HQ
SMM and Influencer Marketing
A Modern Phenomenon. Creating a New Frontier Of Virtual Opportunities.
Influencer marketing involves marketing products and services to those who have sway over the things other people buy. This market influence typically stems from an individual’s expertise, popularity or reputation. Marketing to an audience of influencers is similar to word-of-mouth marketing, but it does not rely strictly on explicit recommendations.
Social media have been crucial in revitalizing this instrument, creating greater and better opportunities for its use. While in the past, branding has been focused exclusively on well-known personalities, it has later moved to well-known bloggers and today it is about everyday consumers who have a huge impact. More and more brands and companies are focusing on their marketing activities to find new opportunities for presenting themselves. They are looking for someone to ‘tell’ their story.
Who Is An Influencer?
Every time you go online, you’ll interact with influencers. Whether you’re watching a video from your favorite YouTube vlogger, picking up recipes from a chef on Pinterest, or reading the latest Facebook story about your favorite celebrity, you’re engaging with an influencer. These are the people who are at the forefront of social trends. They could be innovators, who create new ideas, concepts or content, that grabs the attention of social media on a regular basis. Or early adopters. Those that discover trends before anyone else, and invigorate them with their own creativity, spreading them further into the social medium.
Influencers have their finger on the internet’s pulse, and social media users listen to them.
The 3 Types of Influencers.
Generally, when the industry talks about influencers, they categorize them into 3 levels based on their potential reach. For ease, they’ve been ranked the same here as...
The Celebrities These are the biggest players and probably a brand within their own right. They’re TV and movie actors, sports and music stars, and social media masters, with around 1 million-plus follower.
The Execs These are your macro-level influencers. Here, you’ll find journalists, bloggers, industry experts, and other content creators, with between 10,000 to 1 million followers.
The Everyday This is the lowest level of social media influencers, but there are more of them than the other two levels combined. With 500 to 10,000 followers, they could be your employees or even vocal customers. You can include your day-to-day consumers in this category too, encouraging them to generate content for you.
Top Influencer Marketing Platforms
  • Klear
  • Upfluence
  • ASPIREIQ
  • Tagger
  • #paid
7 - Mobile Marketing

Single Dating Site In Usa

People have grown pretty fond of their phones. Their little devices of metal, plastic, and glass are like phantom limbs and they panic if they forget it, even for a few hours. This addiction means that consumers have become used to having their mobile devices with them constantly. So what opportunity does this pose for marketers? Right you are. A big one.
The Process
Effective mobile marketing is a cycle of discovery. Since it is a relatively new channel, there is no real rule book to follow so you will need to experiment with and augment your strategy as you go along.
As a digital marketer, if you want to reach the widest audience the smartphone is your new best friend because it helps you to reach a mass audience in an incredibly easy way. For example, Citigroup has found that while TV took 13 years to reach an audience of 50 million users, an entity like Facebook took only 3.5 years. (and Angry Birds took just 35 days :)
The sheer size of the mobile audience and the speed with which you can reach it is incredible. You instantly have a marketplace and an ecosystem that is global, with devices in the hands of everybody that you want to reach, and even a distribution mechanism that facilitates reaching them.
The key benefits of mobile include:
Personal Connection. Gone are the days of so-called brochure websites that contained merely a brand's logo, contact details, and location. With mobile, you can become a social media butterfly and create engaging ads that beg to be noticed whatever you choose, you can connect with users on their personal devices to form deeper relationships.
Access/Immediacy. People's phones are always with them, and unlike newspapers, they do not throw them away. Generally, their phones are always on, too so when you send a notification, it will be noticed. How quickly will it be seen? Well, 37 percent of 18- to 24-year-olds will see it within an hour, and 55 percent of those aged 25 to 40 years will see it within three hours. Well, we wouldn't want to miss anything!
On average, people check their phones 150 times a day, which roughly works out (depending on their sleep patterns) to every 6.5 minutes. They interact with their phones more than with any other technology, which means your message will be seen pretty quickly once sent.
Distribution. You have seen how fast an app such as the one for Angry Birds can reach a global audience. That is largely due to app stores such as the iOS App Store and Google Play, which let you reach millions of consumers instantly.
Seamless UX. Thanks to advances in digital wallets and built-in payment mechanisms, users can browse, select, and purchase with a few touches. And if you can provide them with a seamless, interactive experience, how could they not fall for your charms?
Cross-Platform Capabilities. You can use mobile to activate static media, such as print ads more on that in the section on proximity marketing.
Top Mobile Ad platforms
  • Google Ads
  • Bing Ads
  • AdMob is now part of the Google family
  • Airpush
  • AdColony
8 - Content Marketing
Content marketing is a marketing technique of creating and distributing relevant and valuable content to attract, acquire, and engage a clearly defined and understood target audience with the objective of driving profitable customer action.
Content marketing is the opposite of advertising. It’s about engaging consumers with the stuff they really want, in a way that serves your brand’s purposes and ideals, rather than just trying to jam your logo into their periphery. It’s reaching the exact consumers you want, instead of a vaguely defined demo. It’s helpfully providing an experience they want, instead of trying to distract them from the one they came for. In short, it is the very evolution of advertising itself into something more effective, more efficient, and much less odious.
Traditional channels vs Digital channels
The most relevant difference between Content Marketing and Traditional Marketing is the means of distribution. While Traditional Marketing uses TV, radio commercials, newspaper and magazine ads, banner ads, direct mail advertisements, brochures, flyers, billboards, and signs to get its message out, Content marketing uses very different distribution channels like social media, which is the most popular way to publish content (used by 92% percent of content marketers), email newsletters, website articles, blog posts, infographics, videos, webinars, and podcasts, white papers, and e-books.
Talking vs. Giving
Traditional marketing talks about your product or service, to target audiences: why they need it, and how to get it. It attempts to persuade customers to make a purchase, without itself providing value. Content marketing takes a completely different approach. Rather than placing your product before the consumer, you publish material that the target audience finds useful or interesting. You give them something of value, and if you’ve done your job well, they will come back to you when they need your product or service.
Monologue vs. Dialogue
Traditional marketing is one-sided. You send out fliers or TV spots and people can see them, but they can’t interact with your brand, they can’t make questions or leave comments. Content marketing is interactive; thanks to the Internet, it provides the opportunity to have a dialogue with your customers (or potential customers), rather than merely forcing them to listen to your monologue.
Generalized vs. Personalized
Traditional marketing generally involves a message that is transmitted for several months or even years, so it is designed to appeal to as wide an audience as possible. On the other hand, because Content Marketing is about earning the user’s trust, the content needs to be directed towards a smaller, more specific audience so that it speaks to them directly and gives them a reason to engage with you.
Static vs. Shareable
Traditional marketing content is not easily shareable while Content marketing offers the customer something funny, informative, or inspiring, and does so in an interactive forum like social media, where it is easier to share. And because people share what makes them look good, the better the content, the more exposure it will get.
Top Content Marketing Platforms
  • SEMRush
  • StoryChief
  • Rockcontent
  • Contently
  • Buzzsumo
9 - Pragmatic Marketing
The main goal of pragmatic marketing is to try to deliver products almost precisely as specified by the customer. This is what makes pragmatic marketing one of the most efficient ways to deliver.
Pragmatic Marketing is a sophisticated marketing approach defined as a product creation process that continually adapts itself based on experience. During adaptation, the marketing strategy is tested and re-adapted to ensure that the relevance of the customer to the customers’ expectations are met.
Pragmatic Marketing involves a series of product adaptations and tests to ensure that the final product will satisfy the target market. For example, a TV manufacturer designs a TV with specific features for a particular audience. They use pragmatic marketing by testing the TV with a sample of the audience. From the feedback they get from the sample, re-adapting will be done to ensure that it fits well with user demands.
Pragmatic Marketing Rules
  1. An outside-in approach increases the likelihood of product success.
  2. The answer to most of your questions is not in the building.
  3. We are all pragmatic marketers.
  4. If the product team doesn’t do its job, other departments will fill the void.
  5. The building is full of product experts. Your company needs market experts.
  6. Win/loss should be done by someone not involved in that sales effort.
  7. Your opinion, although interesting, is irrelevant.
  8. Only Build solutions for problems that are urgent and that the market will pay to solve.
  9. Positioning drives execution.
  10. Positioning focuses on the problems you solve.
You can compare pragmatic marketing with agile software development. You must test and re-adapt the software until the final result evolves. You must find out what the customer wants to buy. Theoretically, presenting a perfect product in the right way will make it sell quickly.
10- - ReMarketing or Retargetting
Remarketing or Retargeting are terms used to describe the process where the advertisers follow a user or customer via retargeting ad networks and sell a product or a service to a potential customer. Imagine you visit amazon.co.uk and start searching for a cheap laptop under £500 but you cannot make up your mind in that session, so you close the browser and get on with your other work. However, when you browse the internet again for reading news or just socializing, you can see that amazon ads are showing up on those websites with laptops in them and even with prices under £500. That is what retargeting ads do to hit you again and again on cross-devices you are connected to until you are convinced and make a purchase. On average a user may see a regarding ad about 7-10 times before he may be able to make a purchase.
Remarketing is great for many reasons.
  • Reduced cost per impression
  • Better conversion rates
  • Improved ROI
  • Precise targeting
  • Cost-effective branding
Top retargeting Ad networks
  • Adroll
  • Facebook Ads
  • Google Adsense
  • Chango
  • Criteo
Thank You...
submitted byZestyBellstomarketingmadesimple [link][comments]

2021.12.22 09:09 carlalegendsTalenic® Legal Statement

LEGAL ACTIONS AGAINST WEBSITES POSTING FAKE REVIEWS
Many consumers report looking over reviews before purchasing a Talenic product or service. This has been made easier by the Internet and the easy ability for consumers to include reviews. However, it has also given a forum for consumers to post negative reviews about businesses and individuals that portrays Talenic Corporation in a negative light. In some instances, legal action will be taken by Talenic against posters or websites if the conduct amounts to defamation.

Business Defamation

Defamation occurs when a person or entity makes false statements of fact about the Talenic business, a person affiliated with Talenic business, product, or service that causes economic hardship for Talenic business.

Legal Elements of Business Defamation

As the defamed business Talenic have demonstrated the following elements:
  • Some websites made an unprivileged false statement of fact.
  • Some websites' statements caused harm to Talenic business. A defamatory statement may cause Talenic to lose clients or for customers not to use its products or services. Some website statement was made negligently.
  • Some websites' statement was made with malice, meaning having a reckless disregard for the truth.
As a protest against commercial defamation and misleading consumers to buy fake and shoddy products, we will sue relevant enterprises and individuals in the near future. Including but not limited to the following enterprises and entities:
  • Websites that add misleading words in the domain name after Talenic (e.g. Talenicxxxx.). Use domain spoofing to make customers mistakenly think it is a corporate certification website
  • Websites that do not sell U.S. standard models or sell models with misleading, false, and exaggerated product specifications in the U.S. market
  • Websites that created by regional distributors alone but disguised as Talenic global official websites
  • Websites that mislead U.S. consumers through false descriptions and social media accounts
  • Websites that sell counterfeit products at prices lower than those of genuine products
  • Websites that publish false customer reviews to mislead consumers
  • Websites that not qualified as distributors in the United States

RECOGNIZE AND AVOID PHISHING MESSAGES, PHONY SUPPORT CALLS, AND OTHER SCAMS

If you receive a suspicious email that looks like it's supposed to be from Talenic, please forward it to reportphishing@talenic.com
Phishing refers to fraudulent attempts to get personal information from you, usually by email. But scammers use any means they can to trick you into sharing information or giving them money, including:
  • Fraudulent emails and other messages that look like they're from legitimate companies, including Talenic
  • Scam phone calls or voicemails that impersonate Talenic Support
  • Fake promotions that offer fake products and prizes
If you're suspicious about an unexpected message, call, or request for personal information or money, it's safer to presume it's a scam and contact that company directly if you need to.

How to Report Suspicious Emails, Messages, and Calls

If you receive a suspicious email that looks like it's supposed to be from Talenic, please forward it to reportphishing@talenic.com. Report scam phone calls to the Federal Trade Commission (the U.S. only) or to your local law enforcement agency.

REPORT FAKE OR COUNTERFEIT GOODS

You have the legal right to a refund if you’ve bought something that’s fake or counterfeit.
You can also report the seller to Trading Standards or report the seller for fraud. Trading Standards might take legal action against the seller, but they can’t help you to get your money back.

Getting a Refund from the Seller

The amount of time you have to ask for a refund depends on the date you bought the item because the law changed in October 2015.
If You Bought before 1 October 2015
You have the legal right to a refund within a ‘reasonable’ time of you buying the item. The law isn’t very specific on how long you have, but if you’re confident in your approach you should be entitled to a refund within the first 2 months or so.
If you paid for the item over 2 months ago, you’re legally entitled to a partial refund depending on how much you’ve used the item and how long you’ve had it. You’ll have to negotiate with the seller to agree on a fair price. The seller can also give you a genuine version of the item to replace the fake one.

If You Bought on or after 1 October 2015

You’re legally entitled to a full refund on fake goods within 30 days of paying for them.
If it’s been over 30 days but less than 6 months since you paid, the seller is legally able to give you a real version of the item to replace the fake one. However, if they can’t provide a replacement, they’re legally required to give you a refund (up until 6 months after you paid for it).
If you paid for the item more than 6 months ago, you’re entitled to a part refund depending on how much you’ve used the item and how long you’ve had it. It’s harder to do this after 6 months as you could be asked to prove that the item is a fake - try talking to the real brand and asking them to inspect it.

If the Seller Refuses to Give You a Refund

Sometimes sellers argue that items were obviously fake because they were very cheap. They can say you must have known it wasn’t the real thing and use that as a reason not to give your money back. However, they’re breaking the law by selling fake items and your legal rights still apply.

If You Paid by Debit Card

Contact your bank and say you want to use the ‘chargeback scheme’. If the item costs less than $100, you should contact your credit card company and say you want to use the ‘chargeback scheme’. If the item costs between $100 and $30,000, contact your credit card company and say that you want to make a ‘section 75’ claim to get your money back.

If You Paid Using Paypal

Use PayPal’s online Resolution Centre to report your dispute. You must do so within 180 days of paying.
Report the Seller to Trade Standards
Trading Standards looks into criminal activity and prosecute sellers and traders who break the law. You’re not legally obliged to report someone selling fake goods, but it might stop other people from accidentally buying fakes from them in the future.

REPORT THE SELLER FOR FRAUD

As well as reporting them to Trading Standards, you can also report the trader to Action Fraud. You’re under no obligation to do this, but they will register the trader on the national fraud database, which helps them understand the scale of fraud across the USA.
submitted bycarlalegendstou/carlalegends [link][comments]

2021.12.21 19:49 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX

$EDT.TO $EDTXF
Market cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
  1. IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
  2. SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
  3. GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
  4. LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
  5. TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
  6. COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
BONUS POINTS:
  1. ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
  2. SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
  3. IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
  4. NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
  5. ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
GENERAL OVERVIEW
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236toWallstreetbetsnew [link][comments]

2021.12.21 19:46 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX

$EDT.TO $EDTXF
Market cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
  1. IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
  2. SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
  3. GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
  4. LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
  5. TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
  6. COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
BONUS POINTS:
  1. ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
  2. SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
  3. IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
  4. NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
  5. ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
GENERAL OVERVIEW
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236tobiotech_stocks [link][comments]

2021.12.21 19:44 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX

$EDT.TO $EDTXF
Market cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
  1. IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
  2. SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
  3. GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
  4. LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
  5. TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
  6. COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
BONUS POINTS:
  1. ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
  2. SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
  3. IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
  4. NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
  5. ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
GENERAL OVERVIEW
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Usa Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236toBiotechplays [link][comments]

2021.12.21 19:43 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX

$EDT.TO $EDTXF
Market cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
  1. IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
  2. SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
  3. GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
  4. LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
  5. TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
  6. COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
BONUS POINTS:
  1. ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
  2. SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
  3. IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
  4. NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
  5. ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
GENERAL OVERVIEW
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236tobiotech_stocks [link][comments]

2021.12.21 19:34 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX

$EDT.TO $EDTXF
Market cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)100%
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
  1. IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
  2. SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
  3. GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
  4. LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
  5. TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
  6. COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
BONUS POINTS:
  1. ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
  2. SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
  3. IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
  4. NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
  5. ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
GENERAL OVERVIEW
Spectral Medical is a small cap (~$80M USD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236topennystocks [link][comments]

2021.12.20 23:00 DogfreeModsWeekly Announcement Post

Hey Dogfree!
We just wanted to take this time to remind you of a few things if you haven't seen them already.
​
Related subs:
DogfreeHumor - For memes, comics, and other fun.
DogfreeAww - For aww minus the dogs.
DogfreeDating - Find a dogfree love.
DogcultureFree - For those who don't hate dogs but do hate dog culture.
BanPitBulls - For anything anti-pitbull. Please note that BanPitBulls is NOT anti-dog.
Petfree - For anyone who is annoyed with pets.
TalesfromtheDogHouse - For those wishing to vent about a specific dog and its behavior.
​
​
Previous Mod Statements:
The Definition of Dogfree - Dogfree is for those of us who do not like dogs.
Cats are Off Topic - This is not a cat subreddit. Cats are off topic.
Other Pets and Children are Off Topic - Other pets, children, and childbearing preferences are off topic.
Keeping Conversations Civil - Please be civil toward others. If someone is not being civil, please report them.
Letting Dogs Loose is Against the Rules -Don't suggest letting a dog escape.
Mindfulness Outside the Sub - Please be respectful of other subreddits and Reddit users.
Low Effort Content - What it is and how to post about things that fall in this category.
FAQ - Please check if your question can be answered here before posting.
​
Contact the Moderators of Dogfree - Please do not contact individual moderators directly about subreddit business including this account, DogfreeMods.
  • dogfree is its own forum that is not affiliated with any other website or platform, such as YouTube channels, social media pages, merchandise outlets, Discord servers, or other subreddits
submitted byDogfreeModstoDogfree [link][comments]

2021.12.20 06:36 michaelrama[For Hire] High Conversion, Persuasive Copywriting - Sell More Products & Services!

Link To Full Explanation Of Offer
'MILLIONAIRE MAKER' Copywriter At Bargain Bin Prices... For A LIMITED Time Only:
'Highly Persuasive Sales Copy For Discerning Marketers...'
Flood your business with new customers with my battle-tested 'secret sauce' copywriting methods... I'll create persuasive new sales material for your business... reduce your ad spend... get more customers, and actually make a 'return on investment' with my affordable copywriting services.
Not the cheapest, but by far the most SUPERIOR copywriting service available here (and not as expensive as you may think)... there's plenty of services on offer. But do they have the skills to transform your WSO, service, or product into an irresistible offer that customers feel they must buy? More info below.
It converts, or I'll rewrite it free GUARANTEE (even though this has NEVER happened before)... myself and every copywriter I hire goes through rigorous training to ensure they can create sizzling high conversion sales copy with teeth... and powerful enough to compete in the dating, forex/crypto, weight loss, self improvement, and golf niches (the toughest niches to profit from... let alone ROAR with sales).
Dear fellow marketer,
Are you looking for 'battle tested' copywriting talent to sell significantly more products or services?
If so, you're in the right place.
Let me explain:
My name Is Joe Cassius...
And I've been a high-level underground copywriter for the past 8 years.
... and over the past 8 years, I've worked alongside some of the top online copywriters and marketing professionals...
And watched as they meticulously crafted 'wallet snatching' sales copy...
... making themselves and clients obscene amounts of money that I just can't disclose here.
In fact, if you're deep in the marketing game, chances are you've seen my sales copy used by professionals the world over... Some big names include Ewen Chia, Dean Jackson, & Ray Edwards... (plenty more, but I cannot reveal them to protect client interests).
Listen...
If you don't know who they are, don't worry about it.
All you need to know is that I'm about to make one of the CRAZIEST offers in the Warrior Forum 'services' category...
How?
I'll explain more in a sec, but just imagine this:
You wake up tomorrow morning, no pressure to be at work on time...
... no irritating traffic jams to sit through...
... no boss to look over your shoulder...
... in fact, you have complete freedom to roll out of bed when you feel like it... An 'alarm clock' becomes a thing of the past... You crack open your laptop, and wade through the dozens of 'notification of payment received' emails ...
... making $100's, maybe $1000's of dollars, without even lifting a finger.
The absolute best part about it?
Once you have just 1 profitable campaign...
It doesn't take much effort to 'leverage' it into even bigger profits...
... you're free to outsource time consuming tasks, work on things you want (if you feel like it)... and ultimately: Get filthy rich from your internet marketing empire... That's why trying to 'go it alone' can quickly end up frustrating you to the point of wanting to give up.
And if you've tried your best to create your own copy...
It's almost certain you've come across these common problems: Making your offer stand out amongst hundreds of competitors isn't easy... you could easily throw away weeks crafting, tweaking, testing small things on your own letter, but unless you're extremely lucky... it won't make the impact you were hoping for. People NOW more than ever are distracted by their Facebook, Instagrams, Youtube, whatever... the point is, cutting through the BS is crucial – and a 'mediocre' marketing message is NOT going to get through to your 'average Joe' ; unless it is extraordinary, or at least seems that way.
Most importantly... time is of the essence... do you have the time or patience to go through dozens of copywriting books... from authors like Eugene Schwartz, Gary Halbert, Vic Schwab, John Caples... all the way to 'newer' school writers like John Carlton and Michael Fortin... and then even newer copywriters like Ben Settle...
Reading their books, listening to their programs, and watching their seminars could take weeks...
But understanding them takes months...
Not to mention YEARS of effort required to actually hone those skills to a high level...
Basically, what I'm trying to say is this:
Time is money!
And if you're slaving away trying to figure out why your copy doesn't work...
Or all around getting poor results...
It's time to let a professional take over.
... Because in the end, you'll end up saving time, money, and frustration...
And sales that would otherwise have been lost due to a poorly written sales letter...
... suddenly become the 'life savers' you need to reach your financial goals.
In other words...
Hiring a professional from the get-go means you'll have... More sales, more money in the bank, and ultimately more FREEDOM to do the things you want...
Most people think using brute force or 'tricking' people with...
... fake scarcity...
... overly hyping up their products...
... making impossible ridiculous claims...
And more, is the only way to sell...
But this is the 'fake' copywriting I've been railing against for years.
At the very least, they serve as 'red flags' to avoid hiring complete amateurs.
Pro copywriters, on the other hand make your offer sound enticing, so people WANT to buy.
... without the gimmicks and tricks.
That's why hiring a professional is not a 'cost', but an 'investment'...
Because you'll end up making your money back many times over.
But ultimately, it's about your bottom line.
Just about anyone can 'say' they're a copywriter.
But very few have the 'real world' skills to produce consistent, profitable results...
And that's what I'm offering here...
Results.
And if you don't have $1000's to invest in professional copywriting services just yet...
And that's OK.
Because in a moment you'll discover how (and why), I'm going to offer you the same, high level copywriting skills you need for a mere FRACTION of the cost.
But you're probably asking yourself:
If I'm so good at copywriting...
... why am I about to make this 'ridiculous offer' in the first place? (fyi: this is NOT a made-up story like 99% of them out there.)
The truth is, COVID-19 destroyed a lot of livelihoods for many people I know.
And if you've seen or heard the news about Australia...
... then you know things are pretty bad down here.
And this is an opportunity to make some extra money in order to save some friends from losing their homes, livelihoods, and possibly even lives (sad but true... and most people will not tell you when they're at this stage).
But I digress...
I am very fortunate to have had the opportunity to learn and grow from the WF for many years now.
I used to spend hours on here every single day, learning everything about copywriting, SEO, paid traffic, affiliate marketing, and more...
Once I started having success, I slowly drifted away into the wider community, and honed my skills relentlessly.
After seeing how the multi-millionaires really do it...
... I finally 'graduated' to creating sales copy for my own products and services.
After all...
What's the point of spending 20-40+ hours creating insane high-powered sales copy, when I could just write for myself?
But like I said, this is not for me.
This is an EXTREMELY limited time offer to help people I care about...
... and in return, give YOU something of true value at a substantial discount rate (as a 'thank you' for helping me, to help my friends and family).
Anyway, you're probably wondering about the kind of results you can expect... Take this letter as a 'self-evident', compelling piece of copy. It's exactly why you're still reading right now...
And it just gives you a small taste of persuasive power your own sales letter will have.
But words are just words, right?
It means nothing without actual results...
submitted bymichaelramatoforhire [link][comments]

2021.12.15 20:39 MorpheusIndustryThe Great Reset Timeline

I just published this timeline at https://morpheusindustry.medium.com/cfe519536497. It took hundreds of hours, so I would appreciate you taking at least a quick glance.
I will post the first portion here as well, but it's only about one third of the full timeline.
But first, here's an honorable mention (I couldn't find a date): https://www.blackrock.com/uk/individual/products/charities/why-social-housing-deserves-a-place-in-your-portfolio
Some timelines that helped with my research: https://sociable.co/government-and-policy/timeline-great-reset-agenda-event-201-pandemic-2020/
https://www.zodlikeproductions.net/t218-id2020-accenture-deloitte-mastercard-microsoft-rockefeller-foundation-gavi-open-society-foundation-world-economic-forum-covi-pass-commonpass
https://goingdirect.solari.com/timeline-of-key-economic-events-of-the-pandemic/
...
The following is primarily a timeline of information relevant to what is discussed by Klaus Schwab, the Executive Chairman of the World Economic Forum, which describes itself as 'the International Organization for Public-Private Cooperation'. This timeline will present information based on the themes of what Shwab calls the 'Fourth Industrial Revolution', as well as potential crises that could allow for the acceleration of its implementation.
June 22-23, 2001: 'The Dark Winter exercise, held at Andrews AFB, Washington, DC, June 22-23, 2001, portrayed a fictional scenario depicting a covert smallpox attack on US citizens.'
January 14, 2005: 'Atlantic Storm was a ministerial table-top exercise convened on January 14, 2005 by the Center for Biosecurity of the University of Pittsburgh Medical Center, the Center for Transatlantic Relations of the Johns Hopkins University, and the Transatlantic Biosecurity Network. The exercise used a fictitious scenario designed to mimic a summit of transatlantic leaders forced to respond to a bioterrorist attack.'
'During the six hour meeting, the transatlantic leaders wrestled with the enormity and rapid pace of the emerging epidemics of smallpox, the tension between domestic politics and international relations, the challenge of controlling the movement of people across borders, and an international shortage of critical medical resources such as smallpox vaccine.'
September 7-8, 2006: Black ICE (Bioterrorism International Coordination Exercise)
'In the Black ICE scenario six terrorists from South Asia self-infect with smallpox and, while they are at their most contagious, travel by air to Central Asia. During their travel and upon arrival, the terrorists infect as many people as possible with the disease. National response capabilities are quickly overwhelmed and governments call upon international organizations for assistance in areas such as disease diagnosis and interventions, public health and law enforcement investigations, coordinating transportation policies, and managing displaced populations.'
August 26, 2009: Wikileaks Cable: Russia Declines USG Request to Extend Joint Smallpox Research Through ISTC
May 2010: The Rockefeller Foundation publishes: Scenarios for the Future of Technology and International Development. The section titled 'Lock Step' presents a fictitious scenario of a pandemic and its aftermath.
'The Chinese government’s quick imposition and enforcement of mandatory quarantine for all citizens, as well as its instant and near-hermetic sealing off of all borders, saved millions of lives, stopping the spread of the virus far earlier than in other countries and enabling a swifter postpandemic recovery.' (Page 18)
'During the pandemic, national leaders around the world flexed their authority and imposed airtight rules and restrictions, from the mandatory wearing of face masks to body-temperature checks at the entries to communal spaces like train stations and supermarkets. Even after the pandemic faded, this more authoritarian control and oversight of citizens and their activities stuck and even intensified.' (Page 19)
'In developed countries, this heightened oversight took many forms: biometric IDs for all citizens, for example, and tighter regulation of key industries whose stability was deemed vital to national interests.' (Page 19)
March 14, 2013: The U.S. Is Stocking Drugs for a Hypothetical Smallpox Bio-Attack
January 15, 2014: Ahead of the WEF meeting in Davos, Switzerland, Schwab announced that he hoped the WEF would push the reset button on the global economy
January 22, 2014: The WEF publishes its meeting agenda: The Reshaping of the World: Consequences for Society, Politics and Business (PDF)
'Consequently, the United Nations Secretary-General and the Executive Secretary of the United Nations Framework Convention on Climate Change (UNFCCC) agreed with the World Economic Forum jointly to advance public-private cooperation, action and ambition on climate change and broader sustainability issues.' (Page 33)
'Companies that deal with sensitive and critical information such as those in financial services should put cyberattacks at the top of their list of risks. While CEOs and corporate boards are increasingly becoming aware of the threat, not everyone knows how to respond to it effectively. In today’s hyperconnected world, companies need to have dedicated IT teams to constantly monitor technology systems and devise ways to repel cyber attacks. Encryption is another line of defence as is two-factor verification – requiring a username and password; use of biometric information, such as fingerprints and DNA, are also useful techniques.' (Page 42)
2015: Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships
Peter Daszak, President of EcoHealth Alliance: 'Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pancoronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.' (Page 73)
March 14, 2015: Statement by Prime Minister Shinzo Abe at the High Level Segment of the Third UN World Conference on Disaster Risk Reduction
'Japan is working on the reconstruction from the Great East Japan Earthquake based on the idea of 'Build Back Better,' which aims not simply to recover the same situation that existed prior to the disaster, but rather build a society that is more resilient to disasters than before.'
April 3, 2015: The next outbreak? We’re not ready Bill Gates
Bill Gates on how to respond to the next pandemic: 'And then we need to pair those medical people with the military. Taking advantage of the military's ability to move fast, do logistics, and secure areas.' (Timestamp: 6:37)
September 25, 2015: UN adopts new Global Goals, charting sustainable development for people and planet by 2030
'The 2030 Agenda compels us to look beyond national boundaries and short-term interests and act in solidarity for the long-term. We can no longer afford to think and work in silos.
Institutions will have to become fit for a grand new purpose.'
PDF: Transforming our world: the 2030 Agenda for Sustainable Development
November 9, 2015: Journal article co-authored by Ralph Baric: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
December 12, 2015: Klaus Schwab: The Fourth Industrial Revolution: what it means, how to respond
'Engineers, designers, and architects are combining computational design, additive manufacturing, materials engineering, and synthetic biology to pioneer a symbiosis between microorganisms, our bodies, the products we consume, and even the buildings we inhabit.'
'...governments will gain new technological powers to increase their control over populations, based on pervasive surveillance systems and the ability to control digital infrastructure.'
'Modern conflicts involving states are increasingly 'hybrid' in nature, combining traditional battlefield techniques with elements previously associated with nonstate actors. The distinction between war and peace, combatant and noncombatant, and even violence and nonviolence (think cyberwarfare) is becoming uncomfortably blurry.'
'...the tracking and sharing of information about us is a crucial part of the new connectivity. Debates about fundamental issues such as the impact on our inner lives of the loss of control over our data will only intensify in the years ahead. Similarly, the revolutions occurring in biotechnology and AI, which are redefining what it means to be human by pushing back the current thresholds of life span, health, cognition, and capabilities, will compel us to redefine our moral and ethical boundaries.'
January 10, 2016: L'interview de Klaus Schwab
Klaus Schwab when asked about implants and when they will be implemented: 'Certainly in the next ten years. At first we will implant them in our clothes, and then we could imagine that we will implant them in our brains or in our skin. And in the end, maybe, there will be a direct communication between our brain and the digital world. What we see is a kind of fusion of the physical, digital and biological world.'
May 20, 2016: ID2020 holds Inaugural Summit at the United Nations
'...the inaugural ID2020 Summit brought together over 400 people to discuss how to provide a unique digital identity to everyone on the planet, including the 1.5 billion people living without any form of recognized identification.'
'...a public-private partnership is needed to bring together the broad group of stakeholders, provide coordination, and ensure that the best technological innovations are implemented in ways that are appropriate, secure, and sustainable.'
November 11, 2016: WEF: Welcome to 2030. I own nothing, have no privacy, and life has never been better
'Welcome to the year 2030. Welcome to my city - or should I say, 'our city'. I don't own anything. I don't own a car. I don't own a house. I don't own any appliances or any clothes.'
'Everything you considered a product, has now become a service.'
'In our city we don't pay any rent, because someone else is using our free space whenever we do not need it. My living room is used for business meetings when I am not there.'
'My biggest concern is all the people who do not live in our city. Those we lost on the way. Those who decided that it became too much, all this technology. Those who felt obsolete and useless when robots and AI took over big parts of our jobs. Those who got upset with the political system and turned against it. They live different kind of lives outside of the city. Some have formed little self-supplying communities. Others just stayed in the empty and abandoned houses in small 19th century villages.'
'Once in awhile I get annoyed about the fact that I have no real privacy. No where I can go and not be registered. I know that, somewhere, everything I do, think and dream of is recorded. I just hope that nobody will use it against me.'
January 10, 2017: Dr. Fauci: 'There is no question that there will be a challenge the coming administration in the arena of infectious diseases ... there will be a surprise outbreak.'
February 6, 2017: The WEF publishes a video on social media: 8 predictions for the world in 2030: facebookDOTcom/worldeconomicforum/videos/8-predictions-for-the-world-in-2030/10154159674886479/
'You'll own nothing. And you'll be happy.'
'The US won't be the world's leading superpower.'
'You'll eat much less meat.'
'Polluters will have to pay to emit carbon dioxide.'
'Western values will have been tested to the breaking point.'
April 1, 2017: The Rockefeller Foundation awards a grant to Identity2020 Systems Inc.
'Toward the costs of establishing an alliance of governments, non-governmental organizations and private sector companies committed to providing digital identity to populations currently lacking any type of formal identification.'
June 19, 2017: Accenture, Microsoft team up on blockchain-based digital ID network
'...build a digital ID network using blockchain technology, as part of a United Nations-supported project to provide legal identification to 1.1 billion people worldwide with no official documents.'
'The companies unveiled a prototype of the network on Monday at the UN headquarters in New York during the second summit of ID2020, a public-private consortium promoting the UN 2030 Sustainable Development Goal of providing legal identity for everyone on the planet.'
June 28, 2017: World Bank Launches First-Ever Pandemic Bonds to Support $500 Million Pandemic Emergency Financing Facility
July 6, 2017: How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA
'Eradicating smallpox, one of the deadliest diseases in history, took humanity decades and cost billions of dollars. Bringing the scourge back would probably take a small scientific team with little specialized knowledge half a year and cost about $100,000.'
October 2017: Johns Hopkins Center for Health Security publishes: The SPARS Pandemic: A Futuristic Scenario for Public Health Communicators
'From a government standpoint, the current administration is led by President Randall Archer, who took office in January 2025. Archer served as Vice President under PresidentJaclyn Bennett (2020-2024), who did not seek a second term due to health concerns.' (Page 2)
'Responding to Misinformation or Doubt about an MCM Generated by a Prominent Public Figure: Given the ability of powerful, popular figures to reinforce or to undermine public health messages, what steps might health authorities—at either national or local levels—take to reverse the negative effects of BZee’s unintended linkage of Tuskegee and Corovax...' (Page 28)
'On July 9, 2026, a week before Corovax was released for distribution in the United States, the power grid at the Grand Coulee Dam in eastern Washington State experienced a catastrophic failure. While the event did not destroy any infrastructure or result in any deaths, it did cause widespread power outages in Washington, Oregon, Idaho, Montana, and British Columbia. Though power was restored within a day of the initial outage, blackouts continued plaguing these areas over the next three weeks.' (Page 40)
'The group vigorously debated whether it was appropriate for the President to acknowledge the sacrifice that vaccine recipients had made on behalf of their communities or to console them in their grief over that sacrifice.' (Page 64)
'Reports of Corovax side effects began to gain traction. Several parents of children who experienced neurological symptoms after receiving the vaccination sued the federal government and CynBio. The lawsuit was dropped when they learned of compensation funds available through the PREP Act and the National Vaccine Injury Compensation Trust Fund.' (Page 75)
January 2018: World Economic Forum publishes: The Known Traveller: Unlocking the potential of digital identity for secure and seamless travel (In collaboration with Accenture) (PDF)
'Emerging technologies – from biometrics to distributed ledger to machine learning – offer tremendous potential to transform and enhance the global travel security system.' (Page 3)
'Security is increasingly the focus for international travellers and border agencies as a result of growing turmoil and uncertainty due to geopolitical tensions, complex international security policies, the threat of terrorism and the rise of global pandemics.' (Page 8)
February 2018 (Webster definition date): Merriam-Webster Defines 79 Percent of Americans as ‘Anti-Vaxxers’
'Peter Sokolowski, editor at large of Merriam-Webster.com, said that the entry for 'anti-vaxxer' was first added to the online dictionary in February 2018 and hasn’t been revised or changed since. It has always defined it as 'a person who opposes vaccination or laws that mandate vaccination'.'
March 28, 2018: ID2020: Immunization: an entry point for digital identity
'And because immunization is conducted in infancy, providing children with a digital child health card would give them a unique, portable digital identity early in life. And as children grow, their digital child health card can be used to access secondary services, such as primary school, or ease the process of obtaining alternative credentials. Effectively the child health card becomes the first step in establishing a legal, broadly recognized identity.'
May 15, 2018: 'Clade X is a day-long pandemic tabletop exercise that simulated a series of National Security Council–convened meetings of 10 US government leaders, played by individuals prominent in the fields of national security or epidemic response.'
Clade-X-exercise-presentation PDF: 'Clade X Virus Synthesis: Genes for neurologic virulence of Nipah have been inserted into the parainfluenza genome. Virologists with special training and a reasonably outfitted laboratory could make the virus.' (Page 27)
July 16, 2018: How Russia Is Disrupting the World Order NYT News
'Cybermeddling. Method: Undermine elections, trigger power outages, leak emails.'
September 2018: WEF Insight Report: Identity in a Digital World: A new chapter in the social contract (PDF)
'Our identity is, literally, who we are, and as the digital technologies of the Fourth Industrial Revolution advance, our identity is increasingly digital. This digital identity determines what products, services and information we can access – or, conversely, what is closed off to us.' (Page 5)
'Governments are increasingly advancing digital identity systems to support multiple goals: efficient public service delivery, sustained rule of law and robust democratic processes. At the same time, they also have a growing responsibility to ensure that systems and processes do not lead to unconstitutional intrusions into a citizen’s or resident’s privacy, or become a tool for unwarranted surveillance, discrimination and abuse.' (Page 10)
'New technologies such as Internet of Things (IoT) that establish and verify identity of produce can enable an end-to-end supply-chain traceability model.' (Page 11)
'Digital identity systems need technological innovation, robust regulatory frameworks, widespread public trust and acceptance, a design that appeals to consumers and long-term financial sustainability. This makes them ideal candidates for public-private partnerships, with clearly defined roles and incentives for all involved.' (Page 19)
January to August 2019: Crimson Contagion was a joint exercise conducted from January to August 2019, in which numerous national, state and local, private and public organizations in the US participated, in order to test the capacity of the federal government and twelve states to respond to a severe pandemic of influenza originating in China.
March 26, 2019: WHO launches new global influenza strategy
March 26, 2019: UN accuses Blackstone Group of contributing to global housing crisis
'The UN’s housing advisor has accused private equity firms and one of the world’s largest corporate residential landlords, Blackstone Group, of exploiting tenants, 'wreaking havoc' in communities and helping to fuel a global housing crisis.'
June 13, 2019: World Economic Forum and UN Sign Strategic Partnership Framework
'The World Economic Forum and the United Nations signed today a Strategic Partnership Framework outlining areas of cooperation to deepen institutional engagement and jointly accelerate the implementation of the 2030 Agenda for Sustainable Development. The framework was drafted based on a mapping of existing collaboration between the two institutions and will enable a more strategic and coordinated approach towards delivering impact.'
June 27, 2019: Former FDA Commissioner Scott Gottlieb joins Pfizer's board of directors
July 24, 2019 (funding date): 'But just last year, the National Institute for Allergy and Infectious Diseases, the organization led by Dr. Fauci, funded scientists at the Wuhan Institute of Virology and other institutions for work on gain-of-function research on bat coronaviruses.
'A second phase of the project, beginning that year, included additional surveillance work but also gain-of-function research for the purpose of understanding how bat coronaviruses could mutate to attack humans. The project was run by EcoHealth Alliance, a non-profit research group, under the direction of President Peter Daszak, an expert on disease ecology.'
August 5, 2019: Deadly Germ Research Is Shut Down at Army Lab Over Safety Concerns
'The statement said the Centers for Disease Control and Prevention decided to issue a 'cease and desist order' last month to halt the research at Fort Detrick because the center did not have 'sufficient systems in place to decontaminate wastewater' from its highest-security labs.
But there has been no threat to public health, no injuries to employees and no leaks of dangerous material outside the laboratory, Ms. Vander Linden said.
In the statement, the C.D.C. cited 'national security reasons' as the rationale for not releasing information about its decision.'
'The army institute also employed Bruce E. Ivins, a microbiologist who was a leading suspect — but who was never charged — in the anthrax mailings in 2001 that killed five people. Dr. Ivins died in 2008, apparently by suicide.'
August 19, 2019: Blackrock publishes: Dealing with the next downturn: From unconventional monetary policy to unprecedented policy coordination (PDF)
'Going direct means the central bank finding ways to get central bank money directly in the hands of public and private sector spenders. Going direct, which can be organised in a variety of different ways, works by: 1) bypassing the interest rate channel when this traditional central bank toolkit is exhausted, and; 2) enforcing policy coordination so that the fiscal expansion does not lead to an offsetting increase in interest rates.
An extreme form of 'going direct' would be an explicit and permanent monetary financing of a fiscal expansion, or so-called helicopter money.' (Page 2)
'...in a downturn the only solution is for a more formal – and historically unusual – coordination of monetary and fiscal policy to provide effective stimulus.' (Page 8)
'Any additional measures to stimulate economic growth will have to go beyond the interest rate channel and 'go direct' – when a central bank crediting private or public sector accounts directly with money. One way or another, this will mean subsidising spending – and such a measure would be fiscal rather than monetary by design. This can be done directly through fiscal policy or by expanding the monetary policy toolkit with an instrument that will be fiscal in nature, such as credit easing by way of buying equities. This implies that an effective stimulus would require coordination between monetary and fiscal policy – be it implicitly or explicitly.' (Page 8)
August 22, 2019: Symposium sponsored by the Federal Reserve Bank of Kansas City, Jackson Hole, Wyoming: Challenges for Monetary Policy
Fed Chair Jerome Powell: 'Banks and other key institutions have significantly more capital and more stable funding than before the (2007–08 financial) crisis.'
'To address this new normal, we are conducting a public review of our monetary policy strategy, tools, and communications—the first of its kind for the Federal Reserve. We are evaluating the pros and cons of strategies that aim to reverse past misses of our inflation objective. We are examining the monetary policy tools we have used both in calm times and in crisis, and we are asking whether we should expand our toolkit.'
August 26, 2019: U.S. officials fear ransomware attack against 2020 election
September 3, 2019: HHS Purchases Smallpox Vaccine to Enhance Biodefense Preparedness
'As part of ongoing preparedness efforts against biodefense threats, the U.S. Department of Health and Human Services (HHS) will purchase smallpox vaccine, called ACAM2000, to build and replenish vaccine stored in the Strategic National Stockpile (SNS) over the next decade.
Under the agreement announced today, the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), which oversees the SNS, will award approximately $170 million to Emergent BioSolutions...'
September 4, 2019: The Bill and Melinda Gates Foundation spent $55MM on a pre-ipo equity investment into BioNtech, which later partnered with Pfizer to make its mRNA vaccine.
September 5, 2019: CommonHealth Will Enable Android™ Phone Users to Access and Share their Electronic Health Record Data with Trusted Apps and Partners
'Cornell Tech, UC San Francisco (UCSF), Sage Bionetworks, Open mHealth and The Commons Project are collaborating to develop CommonHealth, an open-source, non-profit public service designed to make it easy and secure for people to collect their electronic health record data and share it with health apps and partners that have demonstrated their trustworthiness.'
September 12, 2019 (date of database suspension): Gravitas Exclusive: Why did Wuhan lab take database of '22,000 virus samples' offline?
'The 'Bat Woman' Shi claimed that the database was taken down because of hacking attempts during the pandemic.'
'...the database was actually taken down in September 2019.'
September 17, 2019: Fed runs repo Tuesday amid worries about keeping its benchmark rate in check
'The Federal Reserve conducted a repurchase operation Tuesday involving $53 billion worth of various debt instruments as it seeks to control the level of its benchmark interest rate. It was the first such move in a decade.'
September 17, 2019: Blast sparks fire at Russian laboratory housing smallpox virus
'The smallpox virus survives in two places on Earth: at Vector and at another high-security laboratory at the US Centers for Disease Control and Prevention in Atlanta.'
September 18, 2019: The Johns Hopkins Center for Health Security publishes: Preparedness for a High-Impact Respiratory Pathogen Pandemic
'Nucleic acid (RNA and DNA)–based vaccines are widely seen as highly promising and potentially rapid vaccine development pathways, though they have not yet broken through with licensed products.' (Page 11)
'During an emergency, it should be expected that implementation of some NPIs (nonpharmaceutical interventions), such as travel restrictions and quarantine, might be pursued for social or political purposes by political leaders, rather than pursued because of public health evidence.' (Page 13)
'National governments need to prepare for the deliberate use of a respiratory pathogen.' (Page 14)
'Continued research into the science of attribution, as well as the strengthening of surveillance systems, international collaboration, and implementation of treaty agreements, particularly the Biological Weapons Convention (BWC), are all needed for an effective response to the deliberate use of a biological weapon with a high-impact respiratory pathogen.' (Page 14)
September 18, 2019: Global Preparedness Monitoring Board: A World At Risk: Annual report on global preparedness for health emergencies
'Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.
Progress indicator(s) by September 2020 • Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.' (Page 8)
September 18, 2019: Wuhan Customs Holds 30 Days Countdown to Military Games and Emergency Response Drill at Ports (English translation)
Original source: https://web.archive.org/web/20200129163943/http://k.sina.com.cn/article_2000016880_7735d5f002000krlq.html
September 19, 2019: Executive Order 13887: Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
September 19, 2019: ID2020 Alliance launches digital ID program with Government of Bangladesh and Gavi, announces new partners at annual summit
'Recognizing the opportunity for immunization to serve as a platform for digital identity, this program leverages existing vaccination and birth registration operations to offer newborns a persistent and portable biometrically-linked digital identity.'
September 20, 2019: The World Knows an Apocalyptic Pandemic Is Coming
September 24, 2019: FDA approves first live, non-replicating vaccine (Jynneos) to prevent smallpox and monkeypox
October 8, 2019: AB 1482 'The California Tenant Protection Act of 2019'
'Statewide law that goes into effect on January 1, 2020 and expires on January 1, 2030.'
October 18, 2019: Military World Games opens in Wuhan, ushering in new era
'This edition marks the first time that the Games have been staged outside the military barracks and the first time all the events are held in one city.'
October 18, 2019: Event 201 simulated the effects of a fictional coronavirus originating in bats but passing to humans via pigs.
'The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201, a high-level pandemic exercise ... The exercise illustrated areas where public/private partnerships will be necessary during the response to a severe pandemic in order to diminish large-scale economic and societal consequences.'
'Governments and the private sector should assign a greater priority to developing methods to combat mis- and disinformation prior to the next pandemic response.'
October 25, 2019: Joe Biden: We are not prepared for a pandemic. Trump has rolled back progress President Obama and I made to strengthen global health security. We need leadership that builds public trust, focuses on real threats, and mobilizes the world to stop outbreaks before they reach our shores.
November 17, 2019 (case date): Coronavirus: China’s first confirmed Covid-19 case traced back to November 17
December 12, 2019: Alleged leaked document: Confidential Disclosure Agreement between NIAID, Moderna Therapeutics, Inc. and its affiliates
'mRNA coronavirus vaccine candidates developed and jointly owned by NIAID and Moderna' (Page 105) (Signed by Ralph Baric on Page 107)
December 19, 2019: Bill Gates: 'What's next for our foundation? I'm particularly excited about what the next year could mean for one of the best buys in global health: vaccines.'
December 27, 2019 (case date): Coronavirus: France's first known case 'was in December'
December 29, 2019: Central Bank Gold Hoarding Hits 50-Year High
'...at least 37 developed central banks have participated in significant monetary easing practices like large scale overnight repos and slashing interest rates.'
January 7, 2020: Prediction For 2030: A Government Take Over Of Rental Housing
January 8, 2020: 2019 had the most CEO departures on record with more than 1,600
'A 'staggering' 1,640 CEOs left their posts in 2019, the highest year on record since Challenger, Gray, & Christmas began tracking in 2002.'
January 11, 2020: Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak
'Ralph Baric, a coronavirus researcher at the University of North Carolina, Chapel Hill, notes that of the four known SARS-related bat viruses capable of infecting humans, this one is the most distant from SARS itself. After downloading the sequence last night, his lab immediately began to try to reverse-engineer a live virus from the sequence, which can be helpful to develop antibody tests and to start experiments in animal models. 'If you want to have a strong public health response, you have to do this quickly,' says Baric, who leads one of the few labs in the world that can re-create coronaviruses just from their sequences. (Bureaucratic hurdles would make it difficult for China to ship the actual virus quickly to other countries, he says.)'
submitted byMorpheusIndustrytoconspiracy [link][comments]

2021.12.15 18:07 NoElevator5818Battle Pass commercial - misleading comm practice under EU law?

Wanted to extend the discussion on the misleading commercial poster we got for the battle pass for heroes of reach (original discussion HERE ). The Poster (link) clearly shows a large variety of armor pieces which were not in the battle pass (from what I read on the forums I only assume that it was gutted after the commercial went live).
Would like to hear your opinions if this commercial (which could motivate you to purchase the pass) could amount to misleading commercial practice in some countries. What do you think?
I haven't done much digging around but just for your information, prima facie this quite fits the definition from the EU unfair commercial practice directive at the end of the post (take in account that it is a directive, not a regulation). Full text here
This is not meant as an attack on 343 devs (who I believe have a limited say in this). However, if the higher-ups who, as I understand, decided to gut the battle pass in the last weeks of release I believe they should have adjusted the commercial accordingly.
​
Article 6
Misleading actions
1. A commercial practice shall be regarded as misleadingif it contains false information and is therefore untruthful or in any way, including overall presentation, deceives or is likely to deceive the average consumer*, even if the information is factually correct, in relation to one or more of the following elements, and in either case causes or is likely to cause him to take a transactional decision that he would not have taken otherwise:*
(a)the existence or nature of the product;
(b)the main characteristics of the product, such as its availability, benefits, risks, execution, composition, accessories, after-sale customer assistance and complaint handling, method and date of manufacture or provision, delivery, fitness for purpose, usage, quantity, specification, geographical or commercial origin or the results to be expected from its use, or the results and material features of tests or checks carried out on the product;
(c)the extent of the trader's commitments, the motives for the commercial practice and the nature of the sales process, any statement or symbol in relation to direct or indirect sponsorship or approval of the trader or the product;
(d)the price or the manner in which the price is calculated, or the existence of a specific price advantage;
(e)the need for a service, part, replacement or repair;
(f)the nature, attributes and rights of the trader or his agent, such as his identity and assets, his qualifications, status, approval, affiliation or connection and ownership of industrial, commercial or intellectual property rights or his awards and distinctions;
(g)the consumer's rights, including the right to replacement or reimbursement under Directive 1999/44/EC of the European Parliament and of the Council of 25 May 1999 on certain aspects of the sale of consumer goods and associated guarantees(8), or the risks he may face.
2. A commercial practice shall also be regarded as misleading if, in its factual context, taking account of all its features and circumstances, it causes or is likely to cause the average consumer to take a transactional decision that he would not have taken otherwise, and it involves:
(a)any marketing of a product, including comparative advertising, which creates confusion with any products, trade marks, trade names or other distinguishing marks of a competitor;
(b)non-compliance by the trader with commitments contained in codes of conduct by which the trader has undertaken to be bound, where:
Thanks for the read
submitted byNoElevator5818tohalo [link][comments]

2021.12.14 16:56 twincompassesaretwoI Solved the Mystery of the Entire Gamestop Saga: My Definitive Explanation on (a) The (Minimum) True Short Interest / Public Float; (b) The Meaning of the Official SEC “Gamestop Report”; (c) How Computershare Was Always the Only Answer Without Catalyst!

____________________________________________________________________________________________________________
____________________________________________________________________________________________________________
Table of Contents
Prologue: Did It Ever Occur To You That the Yahoo! Finance Numbers on GME, as of Right Now, Are (Mostly) Correct?
Part I: We All Fail to Deliver Down Here
Part II: Dr. Jim Decosta Travels to the Future a Couple of Decades and Tells the World About Computershare
Part III: Dr. Jim Decosta Travels to the Future a Couple of Decades and Reveals the Direct Counter to Abusive Naked Short Selling
Epilogue: S3 Partners Was An Extremely Important 'Authority' in Dictating the Narrative That Short Sellers 'Closed Their Positions'
____________________________________________________________________________________________________________
​
If I gave the hedge funds and market makers the benefit of the doubt, this is the absolute lowest I would calculate the short interest and public float of GME (I am 99% certain the short interest and public float are higher, and S3 Partners even said so):
​
GME public float earlier this year (1/2021): 46.89M. GME short % of float (1/2021): 226.42% = 106.16 million shares of GME shorted (and never closed).
​
GME float (now on 12/14/21): 62.11 M. GME short % of float (now on 12/14/21): 13.98%.
​
https://finance.yahoo.com/quote/GME/key-statistics?p=GME
https://web.archive.org/web/20210129164718/https://finance.yahoo.com/quote/GME/key-statistics/
​
106.16 M is 13.98% of 759.37 (M) million, which means there are 759.37 (M) million shares of GME in the public float (approximate true minimum right now):https://s3partners.com/notesonfloat.html
​
Short interest of GME now is unknown but at least 226.42% = 106.16 million shares of GME shorted.
​
Did it ever occur to you that the Yahoo! Finance numbers on GME, as of right now, are (mostly) correct? First, you manufacture 100 shares of GME out of thin air with an in-the-money call and immediately exercise it; then you marry a put with it. A married put can hide short interest because it's a long position (100 GME shares) along with one (1) put option position. A married put causes 100 additional shares of GME to now exist beyond the float and dilute it. These counterfeit / phantom / CEBE shares can be used to temporarily or indefinitely resolve a fail to deliver: this does not close the original shorted share and simply dilutes the float. That is, you can replace a shorted share in the 'official count' with a 'long' counterfeit / phantom / CEBE share: now that this has happened, you can publicly announce it on Yahoo! Finance. Because 100 additional 'long' shares of GME now exist in the float to replace 100 'short' shares, you can publicly announce that the number of shares shorted and the short interest both dropped: this is why the number of rehypothecated shares is never announced publicly anywhere, and Dr. Jim DeCosta pointed this out a couple of decades ago as I explain below. The purpose of doing this is to tank the price through insane amounts of dilution and make it appear as though a short squeeze can no longer happen. This is all possible because shares of GME at the DTCC, under the ownership of Cede and Company, are fungible.
​
S3 partners uses this equation to calculate short interest: S3 Daily Shares Shorted ÷ (Float + Synthetic Longs). The numerator will always remain at least 106.16 M because the official SEC 'Gamestop Report' (2021) or Staff Report on Equity and Options Market Structure Conditions in Early 2021 stated that the short sellers never closed the overwhelming majority of their short positions. The denominator has gradually increased over time as the synthetic longs accumulate. Float + Synthetic Longs = 759.37 (M) million shares of GME (minimum).
​
A fail to deliver can happen with a short or long position! I never really understood this sentence till I understood it. A married put actually has two purposes: hiding short interest and diluting the float with counterfeit / phantom / CEBE shares!
​
https://preview.redd.it/pgr28x8xbi581.png?width=1766&format=png&auto=webp&s=9ff18bbe13dfa1a6f5e3e87e59266260a8411564
Here is S3 Partners admitting, just like the official SEC 'Gamestop Report,' that there was no naked shorting, and this includes 'synthetic longs' created by short sales. The short sells were not naked because they were 'covered' with counterfeit / phantom / CEBE shares—hundreds of millions of them!
https://twitter.com/S3Partners/status/1354851186533396481
____________________________________________________________________________________________________________
​
Official SEC 'Gamestop Report' (2021) or Staff Report on Equity and Options Market Structure Conditions in Early 2021:
https://www.sec.gov/files/staff-report-equity-options-market-struction-conditions-early-2021.pdf
​
Direct measures of naked short selling do not exist.
​
https://preview.redd.it/jth3vmk8bi581.png?width=2545&format=png&auto=webp&s=035431f8943d568d0fec72e03d5584f2f7e2220d
Therefore, the SEC and the rest of the world has to use indirect measures of naked short selling.
​
The unusually high amount of short selling raised the question of whether some of the short sales were “naked”—namely, made without arranging to borrow the underlying security. When a naked short sale occurs, the seller fails to deliver the securities to the buyer, and staff did observe spikes in fails to deliver in GME. However, fails to deliver can occur either with short or long sales, making them an imperfect measure of naked short selling. Moreover, based on the staff’s review of the available data, GME did not experience persistent fails to deliver at the individual clearing member level. Specifically, staff observed that most clearing members were able to clear any fails relatively quickly, i.e. , within a few days, and for the most part did not experience fails across multiple days.
​
https://preview.redd.it/ytoy4s0nbi581.png?width=1996&format=png&auto=webp&s=c9a5aab90a38fdbbc47e6d907a7c683503e986f4
The SEC admits itself that fails to deliver can occur either with short or long sales, making them an imperfect measure of abusive naked short selling. Dr. Trimbath has said this.
​
Prerequisite DD (2) about counterfeit / phantom / CEBE shares:
1) The Ultimate DD about the CEBE (Counterfeit Electronic Book Entries) created by the SBP (Share Borrow Program) within the DTCC. Written by Dr. Jim DeCosta on a forum from 2006. Want it to get immortalized on Reddit: https://www.reddit.com/Superstonk/comments/q53qzh/the_ultimate_dd_about_the_cebe_counterfeit/
2) The DTCC (Depository That Clears Counterfeits) is finished. They covered up the fraud that enables naked short selling and are why we will MOASS to epic proportions: https://www.reddit.com/Superstonk/comments/ocds1m/the_dtcc_depository_that_clears_counterfeits_is/
​
Dr. Jim DeCosta said the following about 'good delivery' of counterfeit / phantom / CEBE shares:
​
https://www.sec.gov/rules/proposed/s72303/decosta122203.htm
​
If there are 100 million legitimate shares issued in the stock he or she is contemplating buying, and 300 million 'failures to deliver' or 'loans made to cover a failed delivery' within the system, the prospective investor has the right to know that his purchase of 1 million shares will NOT give him 1% of the voting power of the company, 1% of any dividends distributed, or 1% of any residual equity rights in the case of the dissolution of the company. The SEC has the DUTY to make this crime-preventive information available to the prospective buyer. Otherwise, this investor will have walked into an ambush that the regulators were well aware of because on the day after his purchase there are 400 million shares that can be sold at any instant in time should bad news arrive on the doorstep. You at the SEC are very well aware of the ambush because you have visibility of these 'fails' and 'loans'. Please give us a 'heads up'! Just as the SEC and the public have the right to know of any additional shares being registered by an issuer,* the micro cap investors have the right to know how many 'counterfeit electronic book entries' are on the books at the DTCC and clearing agencies. In other words, how many shares has the DTCC illegally 'registered' unbeknownst to the corporation and its shareholders.
​
Dr. DeCosta is saying 'The SEC has visibility of the fact that the float is more than 70 million shares of GME: 'give us a heads up' that the public float is in the hundreds of millions (or billions of shares).
​
This is all in the spirit of Regulation Full Disclosure or Reg. FD. It is a two way street. It is inherently wrong for two or more shareholders to receive monthly brokerage statements INDICATING THE OWNERSHIP OF THE SAME PARCEL OF 'SHARES/PACKAGES OF RIGHTS'. We would advise the SEC to not get 'faked out' on the concept of 'good delivery'. 'Good delivery' is aninstantaneous phenomenon at the DTCC. Fraudsters can borrow the same shares involved in effecting yesterday's 'good delivery' of shares to create 'good delivery' of today's trade. This allows access of these nonexistent entities into the DTCC via the creation of 'counterfeit electronic book entries' or 'CEBES'.
​
In a nutshell, the current system for clearance, settlement, and delivery in place at the DTCC allow fraudsters to sell nonexistent entities for literally billions of dollars. The Automated Stock Borrow Program at the DTCC converts these nonexistent entities outside the DTCC into 'Counterfeit Electronic Book Entries' (CEBEs) inside the DTCC via 'the borrow' which creates 'good delivery' which, in turn, allows the trade to 'clear and settle' (C and S). C and S allows the DTCC to earn fees, its participants to earn commissions, and its participating market makers to earn 'mark-ups'. The CEBEs can then be sold to anybody because they are commingled with real shares and until all real shares have been removed from the DTCC via share registration programs any sale is PRESUMED to be that of a real share.
​
This screenshot is Gary once again:
​
https://preview.redd.it/hlcwm7brci581.png?width=2545&format=png&auto=webp&s=9dcc9c1b16062772e75c2bca1b738f7c285041ac
Even in the Reg SHO environment the trades done by naked short selling fraudsters still aren’t “settling”. “Settlement” mandates “Good form delivery” of that which was intended to be purchased by the buyer-a “Package of rights” attached to a specific U.S. corporation domiciled in a specific U.S. state. You cannot have “Good form delivery” if that which is being “Delivered” comes from a self-replenishing “Lending pool” of shares provided by the DTCC’s “Automated Stock Borrow Program” (the SBP) especially when that which is delivered to the new buyers brokedealer can immediately be replaced right back into the same “Lending pool” from whence it just came as if it never left at all.
https://www.sec.gov/rules/sro/nasd/nasd2005112/jdecosta112405.pdf
​
The “Automated Stock Borrow Program” at the DTCC allows shares held in “Street name” at the DTCC to be borrowed from an anonymous “Lending Pool” of shares. This allows the firm of the buyer of these nonexistent shares to receive delivery of “something” that at least resembles a legitimate share at first glance*. The problem is that the buying firm is allowed to immediately place these “Shares or share facsimiles” right back into this same anonymous “Lending pool” of shares AS IF THEY NEVER LEFT IN THE FIRST PLACE. THE BUYING FIRM IS THEN HANDSOMELY REWARDED BY THE DTCC WITH THE CASH EQUIVALENT OF THE SHARES DEPOSITED INTO THE POOL AND CHOSEN TO CLEAR THE NEXT FAILED DELIVERY. THIS WONDERFUL ABILITY TO CONVERT A CLIENT’S PURCHASES OF REAL SHARES OR “PSEUDOSHARES” INTO CASH FOR THE USE OF THE BROKEDEALER PROVIDES PLENTY OF INCENTIVE TO KEEP THE “LENDING POOL' FULL TO CAPACITY.* THE SELF-REPLENISHING ASPECT ALSO HELPS KEEP IT FULL TO ADDRESS AS MANY “FAILED DELIVERIES” AS THE SYSTEM WILL GENERATE WHICH IS AN INFINITE AMOUNT IF NO REGULATOR MONITORS FOR THE APPROPRIATENESS OF THE USE OF THE “BONA FIDE” MM EXEMPTION FROM BORROWING BEFORE SHORT SELLING:
https://www.sec.gov/rules/sro/nasd/nasd2005112/jdecosta112405.pdf
​
Fraudsters can 'deliver' counterfeit shares and 'clear any fails relatively quickly.'
​
Some guy with a cat poster in his room was mentioned by Lucy Komisar as saying the following:
Keith Gill, the independent investor whose social media posts started the GameStop frenzy, made the most important comment of the hearing. He pointed out that the same share can be “located” dozens of times, even for multiple clients. And options market makers like Citadel are exempt from the rules that they must locate the stock.
Gill said, “The ability for the same share to be shorted infinite times is a pathology. We don’t have the ability to track what shares are shorted and how many times.”
https://prospect.org/powegamestop-mess-exposes-the-naked-short-selling-scam/
​
The SEC admits the following:
In seeking to answer this question, staff observed that during some discrete periods, GME had sharp price increases concurrently with known major short sellers covering their short positions after incurring significant losses. During these times, short sellers covering their positions likely contributed to increases in GME’s price:
https://www.sec.gov/files/staff-report-equity-options-market-struction-conditions-early-2021.pdf
​
​
The reported short interest of GME according to Yahoo! Finance was the following:
​
Short percentage of float (Jan 14, 2021): 226.42%
Short percentage of shares outstanding (Jan 14, 2021): 88.58%
​
https://web.archive.org/web/20210129164718if_/https://finance.yahoo.com/quote/GME/key-statistics/
​
Short percentage of float (11/12/20): 297.13%
Short percentage of shares outstanding (11/12/20): 103.52%
​
https://web.archive.org/web/20201130212429if_/https://finance.yahoo.com/quote/GME/key-statistics/
​
Official GME SEC report
Figure 6 shows that the run-up in GME stock price coincided with buying by those with short positions. However, it also shows that such buying was a small fraction of overall buy volume. It was the positive sentiment, not the buying-to-cover, that sustained the weeks-long price appreciation of GameStop stock . . . . A short squeeze did not appear to be the main driver of events:
https://www.sec.gov/files/staff-report-equity-options-market-struction-conditions-early-2021.pdf
​
The shorts closing their position was a small fraction of the run-up in GME stock price in 1/2021. Buying to cover or closing the short positions did not account for the majority of the run-up in GME stock price in 1/2021. A short squeeze did not appear to be the main driver of events: this means the abusive naked short sellers did not close an overwhelming majority of their short positions.
​
https://preview.redd.it/czijhz1mdi581.png?width=1471&format=png&auto=webp&s=dcc01b782f09ef7700e469168568814ddbb36054
​
Abusive naked short sellers can then use a million different ways to buy time to fail and never deliver (short-kiting, etc.), hide short interest, and manipulate price of GME with more than one way including shorting XRT, dark pools, etc. Here's one way: u/broccaaa said, “When prices really started to move from January 25-29, more than 100 million shares were created with Deep ITM call (exercised) and married-put naked shorting and used to hammer down price and hide short interest.”
​
Naked short the GME public float at least 226% (outstanding float > 100%) along with having the short interest later drop to < 10-15%; not close the overwhelming majority of your naked short positions; and 'clear fails relatively quickly' or 'not experience fails'—this series of events only makes sense if (a) naked shorts were never covered, (b) the public float is in the hundreds of millions (maybe more than a billion) shares, (c) the publicly reported short interest is hidden with tactics that evade REG SHO regulations along with S3 conveniently using a new formula to calculate short interest this year. All of this is consistent with the official SEC 'Gamestop Report' or Staff Report on Equity and Options Market Structure Conditions in Early 2021.
​
Dr. DeCosta:
Once into the DTCC all shares, real and fake, are conveniently held in an anonymous pooled format which camouflages the existence of the fake shares. The real and fake shares then play a gigantic game of 'musical chairs' at the DTCC, circling around chairs the number of which match the number of 'real' shares only. But since the music never stops at the DTCC, i.e., no periodic aging and quantification analyses of failed deliveries and loans made to mask failed deliveries, the fraud goes on undetected and the shareholders never do figure out if they bought real or fake shares.
https://www.sec.gov/rules/proposed/s72303/decosta122203.htm
​
There are a million and one ways to engage in abusive naked short selling, hiding short interest, indefinitely fail to deliver a share: Often traders assist each other to avoid having to deliver shares.
​
Dr. DeCosta:
5) In (3) (i) what keeps a crooked MM from just naked short selling through a different proprietary or non-proprietary account once he's caught? Please refer to the Sedona case modus operandi. These people usually work in collusion with many other co-conspirators both on and offshore*. A MM caught misbehaving can hand the naked short selling torch to a 'buddy MM' for 90 days and return the favor should the 'buddy MM' get caught. The emphasis has to be on shutting down the abusive naked short selling of the abusive BROKERAGE FIRMS, NOT JUST THE OFFENDING ACCOUNTS. IF YOU ACTUALLY PUNISH THE BROKERS, THESE CRIMES WILL BECOME LESS PERVASIVE.
https://www.sec.gov/rules/proposed/s72303/decosta122203.htm
​
Dr. DeCosta advocates for punishing brokerages like Fidelity or Vanguard here, by the way. A market maker like Citadel can hand off the naked short selling torch to a buddy market maker and indefinitely delay delivery of a legitimate share.
​
Dr. DeCosta:
Addendum 'C' to the rules and regulations of the NSCC, set up a 'Lending Pool' of shares in street form to cover failed deliveriesFOR ONLY A DAY OR TWObecause there are indeed legitimate reasons why delivery might be held up for a day or two. A year or two would seem to be a little excessive.Be aware also of the constant 'kiting' of these 'open positions' amongst the perpetrators of this fraud and their co-conspirators made in an effort to 'freshen up' the ages of these 'fails' and 'loans'.
​
In order to deal with a short sale where the investor becomes aware that the needed shares cannot be borrowed, the use of short-kiting helps to buy some additional time. The investor establishes another short sale through a differentbrokerageand uses the proceeds to cover the initial short sale. In the interim, the investor is able to borrow the needed shares to complete the position created with the short-kiting strategy and the outcome is favorable for all parties concerned.
https://www.wise-geek.com/what-is-short-kiting.htm
https://www.investopedia.com/terms/k/kited.asp
https://www.reddit.com/Superstonk/comments/mxnou5/til_about_the_term_kiting_aka_fail_to_delive
​
Dr. Decosta:
It really doesn't matter whether the actual initiator of the naked short sell order was a predatory financier selling death spirals, an offshore corporation set up in a tax haven with strict banking secrecy laws, an unregulated hedge fund, an Internet naked short selling 'guru' or one of his disciples, a Canadian brokedealer, etc. All of these orders go through U.S. market makers, U.S. clearing firms, and the DTCC.
https://www.sec.gov/rules/proposed/s72303/decosta122203.htm
​
Dave Lauer on Merrill recently: There are a few interesting nuggets in this action. For example, it also suggests that Merrill traders used derivatives in overseas affiliates to net against short positions in the US to avoid marking orders as short. That seems like a big deal: https://twitter.com/dlauestatus/1446468778062123046
________________________________________________________________________________________________________
​
Contrary to popular belief, S3 Partners changed the way they calculated short interest as early as 9/2020, around the time that King Kong became the largest shareholder of GME (not around 2/2021 or so):https://web.archive.org/web/20201001000000*/https://www.shortsight.com/short-interest-of-float-2-0/
​
Another post on calculating short interest by S3 Partners: Notes on Float: S3’s Ihor Dusaniwsky Answers Your Burning $GME Questions: https://s3partners.com/notesonfloat.html
We calculate short interest daily .... the most up to date numbers you can get on the street! https://twitter.com/ihors3/status/1354491420015546369
S3 Partners initially agrees with the official SEC 'Gamestop Report' by saying this was a long-buying rally and not a short squeeze: https://twitter.com/ihors3/status/1354533284345163776
Illegal naked short selling is short selling without a locate and not being able to settle your trade. But in my scenario every short got a locate and a stock borrow and all settlements are satisfied. Rehypothicating or margining shares for stock loan is a necessary function.
https://twitter.com/ihors3/status/1354914850355507202
Per @S3Partners data, while the “value shorts” that were in $GME earlier have been squeezed, most of the borrowed shares that were returned on the back of the buy to covers were shorted by new momentum shorts in the name: https://twitter.com/ihors3/status/1355234358194556928
Our float number includes the 'synthetic longs' that are created from short selling. This is an accurate calculation of the actual tradable liquidity in the market. shares shorted / (float + shares shorted)
https://twitter.com/ihors3/status/1355197063504547841
​
Ask yourself why they changed the equation to calculate short interest as early as 9/2020. Then see the following tweet:
​
#BREAKING: New S3 Partners Data Reveals Decline in $GME Short Bets. #s3data
https://twitter.com/S3Partners/status/1356017621649383426
​
​
P.S. This is not my 'nuclear' DD. I found all this shit out while preparing my 'nuclear DD.'
________________________________________________________________________________________________________
Disclaimer:
The information in this presentation does not, and is not intended to, constitute financial advice. I am expressing my personal opinion as if we were having a conversation at a diner or a bar. I am an active shareholder of Gamestop stock.
The views expressed is this presentation are my own, and they do not constitute an endorsement, recommendation, or approval by any other person or entity. References made to others are only for informational purposes for your convenience, and anyone mentioned here is not responsible for the accuracy or legality of any of the content published by me. Gamestop is not affiliated with any person or entity mentioned in this video or reddit post.
The content of this post is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.
All opinions expressed by me are solely my opinion and do not reflect the opinions of anyone else.
You should not treat any opinion expressed on this message as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information I consider reliable, but I do not warrant its completeness or accuracy, and it should not be relied upon as such.
I am not under any obligation to update or correct any information available on this website. I am an active shareholder of Gamestop stock.
Also, the opinions expressed by me may be short term in nature and are subject to change without notice.
I do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed from my reddit account. Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives, financial situation or needs and is not intended as recommendations appropriate for you.
You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
The content on this posting is provided 'as is;' no representations are made that the content is error-free.
None of this is insider trading and is all publicly available information.
Thoroughly researching a company, performing your due diligence, and long-term investing into a stock you like is strongly encouraged. Market manipulation is illegal and is totally discouraged.
You should be aware of the real danger of investment frauds and scams.
Disclaimers made in this presentation may be applicable to all statements made on this reddit account.
https://www.sec.gov/oiea/investor-alerts-bulletins/ia_rumors.html
https://www.sec.gov/investoalerts
https://www.sec.gov/oiea/investor-alerts-and-bulletins/risks-short-term-trading-based-social-media-investor-alert
submitted bytwincompassesaretwotoSuperstonk [link][comments]

2021.12.13 23:00 DogfreeModsWeekly Announcement Post

Hey Dogfree!
We just wanted to take this time to remind you of a few things if you haven't seen them already.
​
Related subs:
DogfreeHumor - For memes, comics, and other fun.
DogfreeAww - For aww minus the dogs.
DogfreeDating - Find a dogfree love.
DogcultureFree - For those who don't hate dogs but do hate dog culture.
BanPitBulls - For anything anti-pitbull. Please note that BanPitBulls is NOT anti-dog.
Petfree - For anyone who is annoyed with pets.
TalesfromtheDogHouse - For those wishing to vent about a specific dog and its behavior.
​
​
Previous Mod Statements:
The Definition of Dogfree - Dogfree is for those of us who do not like dogs.
Cats are Off Topic - This is not a cat subreddit. Cats are off topic.
Other Pets and Children are Off Topic - Other pets, children, and childbearing preferences are off topic.
Keeping Conversations Civil - Please be civil toward others. If someone is not being civil, please report them.
Letting Dogs Loose is Against the Rules -Don't suggest letting a dog escape.
Mindfulness Outside the Sub - Please be respectful of other subreddits and Reddit users.
Low Effort Content - What it is and how to post about things that fall in this category.
FAQ - Please check if your question can be answered here before posting.
​
Contact the Moderators of Dogfree - Please do not contact individual moderators directly about subreddit business including this account, DogfreeMods.
  • dogfree is its own forum that is not affiliated with any other website or platform, such as YouTube channels, social media pages, merchandise outlets, Discord servers, or other subreddits
submitted byDogfreeModstoDogfree [link][comments]

2021.12.11 00:08 PlayPUBGMobilePUBG MOBILE - 1.7 To Carry or Be Carried - Full Rules

PUBG MOBILE CONTEST OFFICIAL RULES
  1. No Purchase Necessary; Entry Instructions. No purchase or payment of any money is necessary to enter. A purchase will not improve the chances of winning.
ODDS OF WINNING WILL DEPEND ON THE TOTAL NUMBER OF ELIGIBLE ENTRIES RECEIVED AND ON THE SKILL OF THE ENTRANT. VOID WHERE PROHIBITED BY LAW OR WHERE REGISTRATION, BONDING OR LOCALIZATION REQUIRED. SUBJECT TO ALL NATIONAL, REGIONAL AND LOCAL LAWS.American
The participation rules for this Contest (“ PUBG MOBILE - 1.7 To Carry or Be Carried ”) are available at the page which linked to these Official Rules (https://www.reddit.com/PUBGMobile/comments/rdimpk/pubg_mobile_17_to_carry_or_be_carried_community/) By posting or submitting an Entry, you are accepting the rules on the Promotion, these Official Rules and the Sponsor’s Terms of Service available at. Time and eligibility of Entry will be determined by Sponsor in its sole discretion. Sponsor will announce the winner through Facebook, Twitter, Twitch or any other social media channel (collectively, “Social Media Channels”) by which the participant participated or by other means consistent with the Promotion. All Entries must meet the following criteria:
· Entries must be original and not violate any third-party rights, and the entrant must have all rights necessary to submit the Entry.
· Entries may not contain material that is obscene, defamatory, libelous, threatening, pornographic, racially or ethnically offensive, or encourages conduct that would be considered a criminal offense, give rise to civil liability, or violate any law. Entries must be appropriate for viewing by the general public; appropriateness will be determined by Sponsor.
In the event of a dispute as to any entrant, the authorized holder of the associated account, email address or user name will be deemed to be the entrant. The “authorized holder” is the natural person assigned an account, email address or user name by an Internet access provider, online service provider, Social Media Channel or other organization responsible for assigning accounts, email addresses or user names. Each potential winner may be required to show proof of being the authorized holder. Sponsor will make final determination of identity of participants and timing of entries in its sole discretion.
  1. Eligibility. Entrants must be 13 years of age or older at the time of entry. Employees, officers and directors of this Promotion's hosting company, and each of their respective parents, affiliated companies and subsidiary companies, and their advertising, promotion, or production agencies, prize providers, Web masters and Web suppliers, and each of their respective officers, directors, employees, representatives and agents (collectively, with Sponsor, the “Promotion Entities”), and their IRS dependents, immediate families (spouse and parent, child, sibling and their respective spouses, regardless of where they reside) and/or members of their households, whether or not related, are ineligible to participate in this Promotion. By participating, entrants agree to these Official Rules and the decisions of the Sponsor, which are final and binding in all matters related to this Promotion. .
  2. Prizes. The Prizes for winning the promotion are as indicated on the Promotion Page. The prize(s) will be subject to the terms of the issuer. No substitution, assignment or transfer of the prize(s) is permitted, except by Sponsor, who has the right to substitute a prize with another of comparable or greater value. TAXES AND ANY OTHER COSTS, IF ANY, RELATED TO THE PRIZE ARE THE RESPONSIBILITY OF THE WINNER.
  3. Winner(s). Sponsor will select the number of winners as indicated on the Promotion Page. The winner(s) of the Promotion will be determined based on demonstrated skill in the area specified on the Promotion Page. Judging will be done by Sponsor or its designees.
In the event a potential winner is disqualified, the prize will be given to the next entrant eligible to win a prize based on the judging criteria. The winner will be attempted to be notified via their supplied contact information and will have fourteen (14) days from notification to accept the prize. Sponsor is not responsible for any delay or failure to receive notification for any reason, including inactive account(s), technical difficulties associated therewith, or winner’s failure to adequately monitor any account. Except where prohibited by law, participation in the Promotion constitutes participant’s consent to Sponsor’s use of participant’s Entry, name, likeness, voice, opinions, biographical information, and residence for promotional purposes in any media without further payment or consideration. Winner (and winner’s guest, if applicable) may be required to sign an affidavit of eligibility, liability release and a publicity release that, among other things, will further allow Sponsor to use a winner’s name, likeness, voice, opinions, biographical information, and residence for publicity and promotional purposes without further compensation where permitted by law.
  1. Conditions of Participation. By submitting an Entry for this Promotion, you agree to abide by these Official Rules and any decision Sponsor makes regarding this Promotion, which Sponsor or its designees shall make in their sole discretion. Sponsor reserves the right to disqualify and prosecute to the fullest extent permitted by law any participant or winner who, in Sponsor’s reasonable suspicion, tampers with Sponsor’s site, the entry process, intentionally submits more than the allowed entries, violates the Promotion Page terms or these Official Rules, or acts in an unsportsmanlike or disruptive manner.
  2. Intellectual Property: Ownership of the pre-existing underlying intellectual property of the entrant remains the property of the entrant subject to Sponsor’s rights to reprint, display, reproduce, perform, use, and exhibit the Entry for the purpose of administering and promoting the Promotion and for Sponsor’s marketing and advertising purposes, including on Sponsor’s website. By participating in the Promotion, each entrant grants to Sponsor a non-exclusive, worldwide, fully paid, royalty-free, perpetual, transferable license to reprint, display, reproduce, perform, use, and exhibit (including the right to make derivative works of) the Entry and materials and information submitted on and in connection with the Promotion or use or receipt of the prize for any and all purposes in any medium. Each participating entrant hereby warrants that any Entry and other materials and information provided by entrant are original with entrant and do not violate or infringe upon the copyrights, trademarks, rights of privacy, publicity or other intellectual property or other rights of any person or entity, and do not violate any rules or regulations. If the Entry or information or materials provided by entrant contain any material or elements that are not owned by entrant and/or which are subject to the rights of third parties, entrant represents he or she has obtained, prior to submission of the Entry and information or materials, any and all releases and consents necessary to permit use and exploitation of the Entry and information and materials by Sponsor in the manner set forth in the Official Rules without additional compensation.
Each entrant warrants that the Entry and materials and information provided do not contain information considered by entrant, its employees or personnel, or any other third party to be confidential, and that the Entry, materials and information provided do not violate any laws or regulations. Entrant represents and warrants that he or she has permission from his employer or school and any necessary third party to enter the Promotion, take and submit Entry, and receive the prize. Entrant agrees that Sponsor has the right to verify the ownership and originality of all Entries and that, upon Sponsor’s request, entrant must submit a written copy of any release or permission entrant has received from a third party granting entrant the right to use such property. Entrant understands and acknowledges that in the event a submission is selected as a winning Entry, and entrant’s ownership, rights and the originality of the Entry cannot be verified to the satisfaction of Sponsor or is in any other way ineligible, Sponsor may select an alternate winner based on the same judging criteria.
  1. Disclaimer, Release and Limit of Liability. SPONSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, REGARDING ANY PRIZE OR YOUR PARTICIPATION IN THE PROMOTION. BY ENTERING THE PROMOTION OR RECEIPT OF ANY PRIZE, EACH ENTRANT AGREES TO RELEASE AND HOLD HARMLESS SPONSOR, ANY THIRD-PARTY SOCIAL MEDIA CHANNELS UTILIZED FOR THE PROMOTION, AND THEIR SUBSIDIARIES, AFFILIATES, SUPPLIERS, DISTRIBUTORS, ADVERTISING/PROMOTION AGENCIES, AND PRIZE SUPPLIERS, AND EACH OF THEIR RESPECTIVE PARENT COMPANIES AND EACH SUCH COMPANY’S OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS (COLLECTIVELY, THE “RELEASED PARTIES”) FROM AND AGAINST ANY CLAIM OR CAUSE OF ACTION, INCLUDING, BUT NOT LIMITED TO, PERSONAL INJURY, DEATH, OR DAMAGE TO OR LOSS OF PROPERTY, ARISING OUT OF PARTICIPATION IN THE PROMOTION OR RECEIPT OR USE OR MISUSE OF ANY PRIZE. THE RELEASED PARTIES ARE NOT RESPONSIBLE FOR: (1) ANY INCORRECT OR INACCURATE INFORMATION, WHETHER CAUSED BY ENTRANTS, PRINTING ERRORS OR BY ANY OF THE EQUIPMENT OR PROGRAMMING ASSOCIATED WITH OR UTILIZED IN THE PROMOTION; (2) TECHNICAL FAILURES OF ANY KIND, INCLUDING, BUT NOT LIMITED TO MALFUNCTIONS, INTERRUPTIONS, OR DISCONNECTIONS IN PHONE LINES OR NETWORK HARDWARE OR SOFTWARE; (3) UNAUTHORIZED HUMAN INTERVENTION IN ANY PART OF THE ENTRY PROCESS OR THE PROMOTION; (4) TECHNICAL OR HUMAN ERROR WHICH MAY OCCUR IN THE ADMINISTRATION OF THE PROMOTION OR THE PROCESSING OF ENTRIES; OR (5) ANY INJURY OR DAMAGE TO PERSONS OR PROPERTY WHICH MAY BE CAUSED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, FROM ENTRANT’S PARTICIPATION IN THE PROMOTION OR RECEIPT OR USE OR MISUSE OF ANY PRIZE. If for any reason an entrant's Entry is confirmed to have been erroneously deleted, lost, or otherwise destroyed or corrupted, entrant’s sole remedy is another entry in the Promotion, provided that if it is not possible to award another entry due to discontinuance of the Promotion, or any part of it, for any reason, Sponsor, at its discretion, may elect to hold a random drawing from among all eligible entries received up to the date of discontinuance for any or all of the prizes offered herein. No more than the stated number of prizes will be awarded. In event that production, technical, programming or any other reasons cause more than stated number of prizes as set forth in these Official Rules to be available and/or claimed Sponsor reserves the right to award only the stated number of prizes by a random drawing among all legitimate, unawarded, eligible prize claims.
  2. Governing Law. These official rules and the promotion are governed by, and will be construed in accordance with, the laws of the state of California and of the United States of America and the forum and venue for any dispute arising out of or relating to these official rules shall be in San Jose, California. If the controversy or claim is not otherwise resolved through direct discussions or mediation, it shall then be resolved by final and binding arbitration administered by judicial arbitration and mediation services, Inc., in accordance with its streamlined arbitration rules and procedures or subsequent versions thereof (“JAMS rules”). The JAMS rules for selection of an arbitrator shall be followed, except that the arbitrator shall be experienced and licensed to practice law in the state of California. Any such controversy or claim will be arbitrated on an individual basis, and will not be consolidated in any arbitration with any claim or controversy of any other party. All proceedings brought pursuant to this paragraph will be conducted in San Jose, California. The remedy for any claim shall be limited to actual damages, and in no event shall any party be entitled to recover punitive, exemplary, consequential, or incidental damages, including attorney’s fees or other such related costs of bringing a claim, or to rescind this agreement or seek injunctive or any other equitable relief.
  3. Entrant's Personal Information. Information collected from entrants is subject to the Sponsor’s Privacy Policy, which is available at https://www.pubgmobile.com/privacy.html.
  4. Winner(s) List. Individuals may request the name of the winners by emailing (email) , within 90 days from the end of the Promotion period.
  5. Sponsor. Sponsor of this Promotion is Proxima Beta Pte Limited.
  6. No Affiliation with Social Media Channels. This Promotion is in no way sponsored, endorsed or administered by, or associated with, the Social Media Channels. You understand that you are providing your information to Sponsor and not to the Social Media Channels. The information you provide will only be used as described in these Official Rules and Sponsor’s privacy policy.
submitted byPlayPUBGMobiletoPUBGMobile [link][comments]

2021.12.07 10:23 BatwaffelBoz Digital Labs Holiday Sale - Up to 73% off through 28 December

https://www.bozdigitallabs.com/plugins/
https://www.pluginboutique.com/deals/show?sale_id=9173#a_aid=605d605c4aba7 Affiliate link.
https://www.jrrshop.com/boz?dir=desc&order=special_from_date Use code: FORUM
https://www.audiodeluxe.com/category/brands/boz-digital-labs?f%5B0%5D=bm_field_on_sale_now%3Atrue
https://www.pluginboutique.com/deals/show?sale_id=8853#a_aid=605d605c4aba7 Affiliate Link.
https://pluginfox.co/collections/boz/promotion?aff=249 Affiliate Link.
https://thefxchain.com/collections/boz-digital-labs?ref=binrozhksqp1 Affiliate Link.
Some of the links here are affiliate links. We receive a commission which helps support the subreddit.
submitted byBatwaffeltoAudioProductionDeals [link][comments]

2021.12.06 23:00 DogfreeModsWeekly Announcement Post

Hey Dogfree!
We just wanted to take this time to remind you of a few things if you haven't seen them already.
​
Related subs:
DogfreeHumor - For memes, comics, and other fun.
DogfreeAww - For aww minus the dogs.
DogfreeDating - Find a dogfree love.
DogcultureFree - For those who don't hate dogs but do hate dog culture.
BanPitBulls - For anything anti-pitbull. Please note that BanPitBulls is NOT anti-dog.
Petfree - For anyone who is annoyed with pets.
TalesfromtheDogHouse - For those wishing to vent about a specific dog and its behavior.
​
​
Previous Mod Statements:
The Definition of Dogfree - Dogfree is for those of us who do not like dogs.
Cats are Off Topic - This is not a cat subreddit. Cats are off topic.
Other Pets and Children are Off Topic - Other pets, children, and childbearing preferences are off topic.
Keeping Conversations Civil - Please be civil toward others. If someone is not being civil, please report them.
Letting Dogs Loose is Against the Rules -Don't suggest letting a dog escape.
Mindfulness Outside the Sub - Please be respectful of other subreddits and Reddit users.
Low Effort Content - What it is and how to post about things that fall in this category.
FAQ - Please check if your question can be answered here before posting.
​
Contact the Moderators of Dogfree - Please do not contact individual moderators directly about subreddit business including this account, DogfreeMods.
  • dogfree is its own forum that is not affiliated with any other website or platform, such as YouTube channels, social media pages, merchandise outlets, Discord servers, or other subreddits
submitted byDogfreeModstoDogfree [link][comments]

2021.12.05 05:20 a_HerculePoirot_fanPSA: Common scams, their modus operandi and tips on avoiding scams

There needs to be more awareness on scams, hence this post. Please note that this is not an exhaustive list, just a few common ones. As it's a long post, I used headings and bullet points to make it more digestible rather than a wall of text. All sources are credited but I left out any, please inform me and I will edit my post.
1. Identifying accounts used by scammers by verifying if a Malaysian Bank Account or Telephone number has been used in an online fraud case or scam:
How: Go on https://semakmule.rmp.gov.my/
2. Blocking spam calls
How: Install Truecaller
  1. Firstly, you are advised to lodge a police report.
  2. Then, to report to the relevant enforcement agency.
  3. You must keep all records and documentations for the investments such as bank-in slips, deposit slips, agreements, vouchers that you received from the company or perpetrator so that you can use the documents to take action against the company.
  4. This includes details of the officers or key persons that you dealt with in the company. This information could prove useful for enforcement purposes.
https://preview.redd.it/958ffumdsm381.jpg?width=544&format=pjpg&auto=webp&s=29d71d1eed642c90897647b0c03363bbeb251ca6
1.​PDRM
2. BNM (Bank Negara)
  • Lodge a complaint using their weblink: https://telelink.bnm.gov.my/
  • Any of the BNM offices (Face-to-face consultations will require appointment made through the weblink or hotline)
  • BNMTELELINK (Contact Centre) Tel: 1-300-88-5465 (1-300-88-LINK)
3.KPDNHEP (complaints regarding goods and services)
  • Toll free number (1-800-886-800)
  • System e-Aduan: http://e-aduan.kpdnhep.gov.my/
4. KPKT (complaints regarding licensed money lenders, usually for illegal money lenders or Along they refer to PDRM)
  • Lodge a complaint on: https://aduan.kpkt.gov.my/aduan-online/entry/aduanperumahan.cfm
  • Call their hotline Bahagian Kawalan Kredit Komuniti (BKKK) on 03-8891 4694/4690
  • Go to Kaunter Aduan KPKT di Aras 1, KPKT di Putrajaya.
5.MCMC(complaints regarding cyber scams which include telecommunications services, broadcasting services, Internet services, postal services, online content problems, USP and more. Check the full list here)
  • Lodge a complaint on: https://aduan.skmm.gov.my/
6. National Consumer Complaints Centre
  • Lodge a complaint on https://ncccaduan.firebaseapp.com/ (but it is currently offline until December 31st 2021)
​
TYPES OF SCAMS
Source: KPDNHEP
Modus operandi: Offering loans via socmed such as FB, Instagram and WhatsApp
Prevention [Source:Harian Metro]
  • Don't fall for low interest rate and 'fast money guaranteed' offer
  • Be physically present at financial institutions or licensed money lenders for loan application instead of through socmed
  • Go on i-KrediKom which was launched on 5th April 2019 for a list of licensed moneylenders or community credit companies registered under the KPKT
Further news articles:
Source: Malay Mail and PIDM
Prevention [Source:Ninjavan]:
  • Keep track of all your purchases.
  • Do not accept parcels / items that you are not expecting, especially if you have to pay for it.
  • Parcel scam is often another form of love scam, in which the scammer will claim to send a parcel with valuable items or money and promise commission/jewelries to the victim but need to pay for “courier service”.
Further news articles:
Source: Free Malaysia Today and PIDM
Prevention [Source:Investright.org and RHB Bank]
  • They cannot meet you in person and avoid video chats.
  • They profess their love early on in relationships and flood you with affectionate messages.
  • They steer the conversation toward finances and ask for money.
  • They may ask for your nude photos or perform sexual acts in front of a webcam and may threaten to spread the photos to family, friends and strangers if you stop sending them money.
  • Love scam is often another form of parcel scam, in which the scammer will claim to send a parcel with valuable items or money and promise commission/jewelries to the victim but need to pay for “courier service”.
Further news articles:
Source: Securities Commission
Prevention[Source: The Edge Markets]:
  • Verify the status of individuals or companies offering investing opportunities via Security Commission’s website and whether they are on the list of unauthorised websites, investment products, companies and individuals.
  • Remember the golden rule - if it sounds too good to be true, it's probably a scam
  • Deal only with licensed financial institutions and authorised dealers
  • Be cautious of investments offered via social media platforms or fake celebrities endorsements
  • Don't be pressured or rushed to invest
  • Be sceptical of any investment opportunity that is not in writing
  • In case an investment has been made, keep copies of all the investment and communications
Further news articles:
Source: Bernama
Financial scam # Type 1: Low loan interest
https://preview.redd.it/px706yeytm381.jpg?width=427&format=pjpg&auto=webp&s=45ee6b49c269da1be0e0e60d2ec2442040881689
How do loans work [Source:Hong Leong Bank]
  • There will always be an official document (printed or digital) which discloses clearly your loan details
  • You will never have to pay any sum upfront as it is illegal for a lender to ask for pre-payment
  • Find out who the borrower is and be sure the loans are from licensed financial institutions since they are regulated by the central bank and therefore the safest option or iKreditKom app by KPKT(Kementerian Perumahan dan Kerajaan Tempatan) which allows people to check whether the lending company is legally registered before making a loan.
  • Licensed financial institutions and/or banks DO NOT appoint or engage third parties or agents for the process of securing loans [Source:ABM (Association of Banks in Malaysia)]
Red Flags [Source:Hong Leong Bank]:
  • A lender who has zero interest in your credit history, and ads that say “No hassle-fast money guaranteed” or “We don’t care about your credit”.
  • Legitimate lenders will only approve loan once they accessed your credit history.
  • The entire loan process takes place via WhatsApp or socmed
  • Upfront payment: Some scammers claim you need to pay a processing fee due to bad credit health
  • Pressured to act immediately: Scammers may pressure you to give personal information or send money before providing proper documentation
Further news articles:
Financial scam # Type 2: Identity Theft
Source: RHB
Prevention: [Source:CIMB]:
  • Always remember to log out once you have completed your banking transactions.
  • Never share details such as your card number / User ID / PIN / password / TAC with anyone or key them in in any website other than the official banking sites
  • Do not click on links or open email attachments from unknown / unreliable senders / sources (Example: Emails from CIMB will always end with u/cimb.com
  • Don’t write your PIN anywhere which is easily accessible to anyone.
  • Never save your card details on your browser.
  • Never use easy-to-guess Card PINs such as date of birth.
Financial scam # Type 3:Mule Account Scam
Source: TheStar and PIDM
Prevention [Source:Maybank and ABM]:
  • Do not allow your account to be used or handled by any third party or unknown persons.
  • Do not share your account bank details i.e. Internet Banking User Name and/or Password, ATM Card, PIN Number or TAC to a third party.
  • Do not be tempted by lucrative job offers with involve you handing over your ATM card/online banking details as enforcement action will be taken against you if you are found to be involved
Further news articles:
Financial scam # Type 4: Email Scam
Source: Public Bank
Prevention [Source:BNM]
  • Use web browsers that are up-to-date with built-in phishing filters.
  • DO NOT trust emails, calls or SMS claiming cash wins or refunds and requesting for personal banking information.
  • Contact your respective banks or contact the Associations of Banks in Malaysia (ABM) toll-free service called ABMConnect at 1-300-88-9980 when in doubt of the email, SMS or calls.
Image example of email scam 1:Beware of email scam requesting for banking information
Image example of email scam 2:Samples of phishing emails
Financial scam # Type 5: Loan Deferment Scam
Source: AmBank
Modus operandi and prevention[Source:Alliance Bank]
  • First, scammers will contact via phones, emails, social media and offer to provide assistance in loan payment deferment application.
  • Next, they will provide a URL to bank lookalike application form for customers to fill in personal & banking details
  • Finally, request for “processing fee” for loan deferment application. Use the bank’s official channels instead of 3rd party agents to get more details on loan deferment.
Source: Malay Mail and PIDM
Modus operandi [Source:scamwatch.gov.au]:
  • A scammer may contact you out of the blue to tell you that you can claim a large inheritance from a distant relative or wealthy benefactor. You may be contacted by letter, phone call, text message, email or social networking message.
  • The scammer usually poses as a lawyer, banker or other foreign official, and claims that the deceased left no other beneficiaries.
  • Sometimes the scammer will say you are legally entitled to claim the inheritance. Alternatively, they might say that an unrelated wealthy person has died without a will, and that you can inherit their fortune through some legal trickery because you share the same last name.
  • You will be told that your supposed inheritance is difficult to access due to government regulations, taxes or bank restrictions in the country where the money is held, and that you will need to pay money and provide personal details to claim it.
Red flags/prevention [Source:scamwatch.gov.au]
  • May look convincing and use official-looking letterhead and logos, but will usually contain spelling mistakes and grammatical errors.
  • Size of the supposed inheritance may be very large, sometimes many millions of dollars.
  • You are asked to provide your bank account details, copies of identity documents as verification, and to pay a series of fees, charges or taxes to help release or transfer the money out of the country through your bank.
  • Do an internet search using the names, contact details or exact wording of the letteemail to check for any references to a scam – many scams can be identified this way.
Source: https://www.agelessonline.net/e-commerce-scams-on-the-rise/
Prevention [Source:nasilemaktech] :
  • Avoid making purchases on FB, WhatsApp and other social media platforms
  • Must have clear description of products
  • Beware of fake websites.
  • Always check the URL for errors/inconsistencies/poor grammar and look out for accessible contact information.
  • Do not believe 100% online reviews and be sure to ask the seller if you have any questions
  • For expensive items on Lazada/Shopee, recommended to buy from “Official Stores” which is 100% legit to ensure legitimacy and genuinity of the product.
  • For e-commerce platforms such as Lazada/Shopee, red flag if seller requests buyers to contact via WhatsApp in product details and insist on avoiding payment through Lazada and payment made directly to their own account.
Source: https://www.reddit.com/malaysia/comments/r7sa6v/is_this_a_scam/ by u/magnum361
Prevention and Identifying fake job offers [Source:Randstad]:
  • Search for jobs advertised on reputable and legitimate employment websites, such as JobStreet (still have to be cautious)
  • Red flag if money is involved and you are asked to transfer money for medical check, work pass application or to attend the job interview
  • The company has no website or official/corporate social media account
  • You did not apply for the job
  • The job is too good to be true and job description is unclear or too short
  • Poor use of the English language with multiple typos and grammatical errors in the job advertisement or text messages, or “job offer” that starts with “Hi dear…”
  • You found the job posting in a random social media community
  • They ask you for your personal information such as your mobile number or ID photo on messaging platforms
Further news articles:
  • Exclusive syndicates scamming job seekers)
Source: Sinar Harian and PIDM
Prevention [Source:CIMB]:
  • Do not respond to SMS or call from unknown person asking for your credit/debit card or online banking details.
  • Do not respond to any SMS or call that claiming it's coming from Bank Negara. Their officer will never call you to ask for your credit/debit card or banking particulars.
  • If someone claiming to be from your card service provider calls you and asks you to confirm the security numbers on the back of the card (the last three digits on the back of the card), you should end the call immediately.
  • Watch out for poor grammar in the SMS.
  • Check your transactions regularly.
Source: MCMC and Bernama
Prevention:
  • If you think a caller is suspicious, or if your caller is constantly pressuring you to disclose personal information,end the call and block the number.
  • Do not panic if you receive a call from someone posing as a BNM staff/MACC/court officePOS Malaysia/bank officepolice/LHDN.
  • Do not keep to yourself and tell a family member.
  • Do not reveal any details about your bank accounts to the caller
  • Do not call the number given by the caller who claim to connect you to for instance, BNM staff or an inspector
  • Verify with the relevant authorities by calling their official number
Further news articles:
Source: Shopee
Common Shopee scams:
Shopee Scam # Type 1: Job scams
  • Scenario 1:A job offer that requires you to pay to get paid
  • Scenario 2:The same job scam with an upgrade
How to avoid [Source:Shopee Online Shopping Safety Tips]
  • Shopee does not employ any individuals to recruit employees through messaging platforms
  • Shopee also confirms that there is no such role as “Online Purchasing Agents”
  • Shopee will never request for advance payment or deposits as a requirement to work with them.
  • Screenshot conversation as proof when reporting to the authorities
Further news articles: Shopee and Lazada online purchasing agent job offer is a scam
Shopee Scam # Type 2: Stealing personal/bank account details through SMS/phone calls/Fake Seller Centre Scam
  • Scenario 1:Scammers steal bank account details via SMS/phone calls
  • Scenario 2:Scammers requests for OTP after victim places an order on Shopee
  • Scenario 3: Scammer impersonates to be victim's friend on social media
  • Scenario 4:Scammers steal seller Shopee account details via SMS/WhatsApp
How to avoid [Source:Shopee Online Shopping Safety Tips]
  • Do not call the number stated in the SMS
  • Contact respective bank using the contact number stated at the back of your card for any queries
  • Do not share OTP with anyone including family and friends and Shopee will never ask for OTP
  • Shopee will only contact users/sellers via official channel such as Official FB page or through Shopee app notification.
Shopee Scam # Type 3: Payment Scam
  • Scenario 1:Scammer targets users through sponsored posts impersonating to be Shopee
  • Scenario 2:Scammer impersonating as Shopee on unofficial channels for campaigns/giveaways
  • Scenario 3:Scammers request direct payments out of Shopee via WhatsApp/Line/Wechat
  • Scenario 4: Scammers request refund for overpaid orders
  • Scenario 5:Scammers pressure victims into making direct bank transfers
How to avoid [Source:Shopee Online Shopping Safety Tips]
  • All finance-related activities should be strictly done through Shopee App and Web only, and when in doubt, check with the authorities or Shopee’s customer service
Shopee Scam # Type 4: Shopee unofficial channel/fake Shopee website scams
  • Scenario 1:Scammers steal victim's login information via phishing websites
  • Scenario 2:Scammers use pop-up ads on websites to gain victim's trust and information using Shopee logo
  • Scenario:Scammers attempted to get the victim's personal details via private message on social media
How to avoid [Source:Shopee Online Shopping Safety Tips]
  • All announcements for Shopee campaigns or prizes will only be made through official Shopee channels
  • Shopee will only reach out to campaign/contests/giveaway winners through official page/Shopee app notification
  • All Shopee vouchers will only be distributed through their official channels-Shopee App, Shopee website and official social media accounts only.
  • Shopee will only contact users/sellers via official channel such as Official FB page or through Shopee app notification.
Shopee Scam # Type 5: Parcel Scam
  • Scenario 1:Scammers contact victim that they might have an unclaimed package via SMS/phone calls
  • Scenario 2:Scammers send out a message through social media platforms to inform that victim has won a prize
How to avoid [Source:Shopee Online Shopping Safety Tips]
  • Beware of messages/links from unknown individuals asking for OTP/verification codes
  • Always keep count on the orders you have really made from Shopee
Shopee Scam # Type 6: Fake Products
  • Scenario: Tech-related item scams on Shopee such as USB Drives, SD cards and also external hard drives.
How to avoid (credits to u/PRSXFENG): 1. The seller usually has poor English 2. The ships from address is usually invalid (00000 postcode), so you can't return it for refund. 3. 1TB storage drives are still quite expensive, you're not getting a RM15 1TB USB drive, it's a scam, the drive will show 1TB when plugged in but you'll loose data soon, so compare prices with well known brands. 4. Seller usually give a lot of free gifts 5. Seller usually has a bunch of useless keyword texts thrown in like FREE SHIPPING, FAST SHIPPING 24 HOURS, LOCAL SELLER, TRUSTED, HUGE DISCOUNT 6. Check 1 star reviews for call-outs (eg, h2testw) 7. Disregard Shopee's 'authentic product guaranteed', I've seen known scams with that tag (eg, Huawei, Oppo, Vivo and Xiaomi branded microsd cards, they do not exist) 8. Seller name is usually a mash of letters that looks like someone mashed their keyboard.
Lazada Scam # Type 1: Fake Lazada contests and giveaways
Source: [Lazada Singapore]
How the scam works and what you should do [Source: Lazada]:
  • Scammers lead you to a phishing site and gain access to your personal details shared.
  • Only participate in contests that are officially conducted by Lazada on their official channels
Lazada Scam # Type 2: Job scam
Case Study 1:Purchasing products to “increase traffic and clicks” and promising commission byu/liamkohwil: Thread: “Update: Scamming through Lazada. PLEASE HELP
Case Study 2: Fake Lazada Affiliate Marketing Group by u/roboukiiscool: Thread: “Prevalent Scam to watch out for: Lazada Affiliate Marketing Group
How the scam works byu/roboukiiscool:
  1. You help them buy 'products' for them in which they will pay you a small % of commission on (in this case 8%)
  2. After purchasing the 'products', you send them a payment slip as evidence of you actually purchasing and they'll supposedly pay you back the original amount of cash you paid for the product AND the commission they promised.
  3. It starts from small amounts such as rm 5 rm 25 rm50 rm100 and you get 8% commission for all these transactions, sounds like easy money and they gain your trust already.
  4. The higher cost transactions will be around rm500 and this is where they'll start to test how far they can take you, they call this the 'vip lounge' or something cringe, so you thinking you're earning easy commission money through making such sales, you let your guard down.
  5. The scammers think they have extracted enough from you then they'll come and give excuses on why they cannot reimburse your cash and commission anymore, late on payment, transaction did not comply etc etc . Basically just ignore and block you after that.
  6. You lose high amount of money from the 'product' you were supposed to be reimbursed back. Not to mention, the 'product' probably doesnt even exist so there's that.
Lazada Scam # Type 3: Making transactions outside of Lazada platform
How the scam works and what you should do [Source: Lazada]:
  • Scammers block your contact after receiving your payment, with no delivery or refund issued.
  • Off-platform transactions are not protected by Lazada, so always buy and transact within the Lazada platform.
What you should do if you are scammed on Lazada (by u/sasa86):
  1. Compile all screenshots, especially the part where the 'seller' promises refund
  2. Make a police report, claiming fraud
  3. Forward a copy of police report and compiled screenshots to Lazada, as the platform strictly prohibits sellers from conducting sales outside the platform
  4. Once Lazada confirms receipt of said report, forward it to the 'seller' together with a copy of the police report AND state that you will pursue legal action if the money is not refunded by XX days
  5. When making statements to police or Lazada or 'seller', be calm and not be too angry when 'seller' replies to ask you for more time or delay, just shut him off and say sorry, please refund by XX days, then don't say anything more than necessary
Source: https://www.carousell.com.my/p/scam-be-aware-of-this-people-and-this-kind-of-email-141458605/
How the scam works:
  1. Scammers typically insist for conversation to take place on WhatsApp instead of Carousel and once payment is made, they will block you. [Case Study:Has anyone here gotten scammed on carousell before]
  2. Scammers claim that they have overpaid and that you need to refund them [Case Study:Beware of this scam]
What you should do:
  1. For expensive items, always insist on COD or Carousell Protection
  2. If item is too cheap, then it's good to be true and likely a scam.
  3. For sellers, recommended not to sell to a user based in another country
  4. Check seller or buyer's ratings and go for the lowest star review instead of 5-star
  5. Report to police as well as Carousell so they can suspend the seller's account
  6. Make offer and wait for it to be accepted so that you can leave a review to warn others
Source: PDRM
Prevention [Source:PDRM]
  • Do not fall for cheap Umrah packages, especially those offered on socmed or WhatsApp (ex: RM2000 for haj and umrah which is unrealistic price after permit, accommodation, transport and food costs are taken into consideration).
  • Check https://www.motac.gov.my/en/semakan/umrah for a list of licensed and approved travel agencies that offer Umrah packages
What to do if you have been scammed:
  • Lodge a police report and also go on https://motac.spab.gov.my/eApps/system/index.do?aplCode=en to lodge a complaint
Further news articles:
Modus operandi[Source: Straitstimes]
  1. The scam works like this: The crooks approach the victims and ask them to try their luck with a scratch card.
  2. In some cases, victims may receive calls about winning a “contest”. They tell the victims they have won a mystery prize and ask them to go to an office to find out what it is.
  3. When they arrive, the con men reveal the 'prize', usually cheap electrical goods, such as foot massagers. The victims are offered the chance to win a more substantial prize, and asked to hand over cash in advance to cover bogus costs such as 'taxes'.
OTHER SCAMS:
submitted bya_HerculePoirot_fantomalaysia [link][comments]

2021.12.01 21:51 drsfmdOwnership of the individual lots on the island

This is somewhat dated, but this source lists each lot by owner. 'TMG' is 'The Michigan Group' aka, the Laginas, Craig Tester, etc.
This site suggests that Dave Blankenship sold his father's lots to the Laginas.
Lots 1 - 4: TMG/DB
Lot 5: Robert Young
Lots 6 - 8: TMG/DB
Lots 9 - 12: Fred Nolan (I assume the Lagina's now own this, but cannot reference it) Now owned by Fred's son Tom, per prospero_duke
Lot 13: J.D. Johnson (apparently sold in 2002, I can't find anything beyond that)
Lot 14: Dan Blankenship
Lots 15 - 22: TMG/DB (the MP is on Lot 18)
Lot 23: Dan Blankenship/ Dave Blankenship
Lot 24: TMG/DB
Lot 25: Allan Kostrzewa (TMG) (NB: He's a producer for the show)
Lots 26 - 32: TMG/DB
So to summarize, the Lagina's appear to own everything other than lots 5, 13, and 25 (though the owner of 25 is affiliated).
submitted bydrsfmdtoOakIsland [link][comments]

2021.11.30 13:04 ZestyBellsWhat is affiliate marketing? Ultimate 2021 guide for beginners

Tips for affiliate marketers
This article helps new affiliate marketers to understand how they can develop their capabilities. It offers top tips on the different types of affiliate websites that you can create, how you make money through commissions, and can drive traffic through promotions. Lastly, we provide our top tips on the tools available through RevGlue to help you create these new capabilities quickly and easily.
What is affiliate marketing?
So, what is affiliate marketing? Well, in simple terms, it’s the practice of recommending a product or service from your website. A customer visits your site and then clicks on a product link to visit a retail merchant site where they purchase that product. The retailer knows that you are the affiliate that has directed the customer to their site via a cookie left on the buyer's PC. Once a sale is made then you as the affiliate earn a commission on that sale.
There are four parties involved in this transaction:
Affiliates
Affiliates are individuals, companies, or groups of people with an affiliate website. The core capability of affiliates is to have traffic on their website and that send potential customers to the retailer website.
Customer
A customer may search for a product through several different methods - on a search engine such as Google or through other online marketing channels such as social media. The results they find could be a mix of retailer websites, content websites, price comparisons,s and/or affiliate websites.
Retailer
The retailer's online store is the entity that is actually selling the product. The journey of a potential customer could begin from a search engine and then go through several intermediary stages – the important thing for affiliates is to be the last click before reaching the retailer site so that their cookie is the freshest!
Affiliate Network
The Affiliate network is the technology hub between the affiliate and the retailer. They provide the affiliate with access to multiple retailers through a common set of tools for tracking sales, lead management, and commission payment handling. Likewise, for the retailer, the affiliate network offers benefits in campaign management offering thousands of affiliates at one location. The tracking, de-duping, payments due to affiliates are all managed by the affiliate network.
What are the most popular types of Affiliate websites?
There are many different types of affiliate websites that all compete to be the last click before a customer reaches the retailer:
  • Shopping Comparison websites such as Comparepanda.co.uk
  • Loyalty, cashback, and reward websites such as Quidco.com
  • Discount Coupon websites such as RevCoupons
  • Content and Review websites such as Reviews UK
  • Group Deal aggregation websites
  • Mobile Comparison and other services comparison websites such as RevMobiles
  • Pay Per Click (PPC) affiliates who generate traffic via paid search campaigns
  • Product feed niche websites for different product types and services
As a result, the affiliates mix could include content websites, email newsletter companies, search engine professionals, individuals with websites, blogs or forums, cashback or voucher websites, RSS engines, article directories, widgets, content writers - who all offer a whole diverse range of different capabilities.
How do affiliates earn commission?
Whilst there are several different types of affiliate campaigns, by far and away the most popular commission type is CPA (Cost Per Acquisition). These campaigns reward affiliates when a confirmed sale or acquisition is completed i.e. purchasing a product instantly from the retailer website, or within the cookie time period. The commission rate is typically a percentage of the product purchase value although it could be capped to a fixed upper amount.
Some merchants also reward lead generation as the research phase of the buying journey is important in Business to Business (B2B) sales. Hybrid campaigns can result which offer a combination of click and lead commissions. For example, a PVC roofing retailer may setup their affiliate campaign to offer 5p for each click to the retail site and then £2 for a unique lead where the customer fills out their contact details plus a percentage on successful orders at a later date when a salesman provides a quote which the customer agrees to purchase. Whilst this type of business arrangement can be very effective, it is actually the case that hybrid campaigns are very rare to find on affiliate networks.
What are the best Affiliate promotional materials?
Based on the affiliate website types mentioned above, the retailers provide a variety of different promotional material to affiliates to use on their websites:
  • Static Links & Deep links for each page are dynamically obtained and altered at the network level
  • Interactive banners in gif, jpg, and flash format
  • Interactive tools in JavaScript or Flash format that contains product images and prices
  • Store information returns information and contents
  • Product Feeds that is raw data provided in a variety of different technical formats (csv, xml or APIs) which contains all product details such as price, name, description, RRP, price, delivery etc. required to setup price comparison websites
  • Discount voucher codes specifically made available via the affiliate networks
What type of site should an affiliate offer?
This is where RevGlue can help.
Our tools provide all the data, plug-ins, templates, and stats that you need to create any type of affiliate website, quickly and easily.
We have teamed with the top UK affiliate networks. All our data sources offer 100% of affiliate network commissions so that you get the best deals from each of your affiliate networks.
We have the most comprehensive set of data types on the market meaning that you can set up new affiliate capabilities across any of the following:
  • Stores - Setup UK shopping directory with leading 5000 e-commerce stores
  • Coupons - Get the latest discount coupons and offers and set up your coupons website or apps.
  • Cashback - create a UK cashback website or app with structured cashback data set.
  • Banners - populate the latest banners in your websites and apps with affiliate deeplinks.
  • Daily Deals - set up daily deals website with discounted deals data obtained from UK retailers.
  • Mobile Compare - setup a dynamic mobile comparison website with an advanced data structure.
  • Broadband & TV- create a UK broadband, tv, and phones comparison website or app in minutes.
  • Product Feeds – setup niche product websites using product feeds available from all leading UK stores
All data sets are available absolutely free for the first 30 days. You can cancel it at any time and there are no long-term contracts at RevGlue. Pay only £60 per data set after the trial of any data set is over.
Once you have access to the data set you to wish to work on. You will be sourcing a designer and a developer to setup your affiliate website. RevGlue provides Free WordPress plugins for each data set so you can quickly setup your affiliate websites such as a cashback website, coupons or mobile comparison website. Browse and download all RevGlue plugins here.
Finally, try RevGlue unique and responsive WordPress templates for your affiliate projects. Each template costs only £99 and you will get fully compatible and responsive files for your WordPress affiliate website.
And then you can exploit all the retailer promotional material available using our RevAds tool to create dynamic ads for your website or mobile apps with flexible sizes, fresh content, and full styling options.
So whether you are a seasoned affiliate looking to add a new capability or a publisher just starting out, there is a whole world of opportunity waiting to be discovered. Take that first step and sign up for a free RevGlue account today.
submitted byZestyBellstomarketingmadesimple [link][comments]

2021.11.29 23:00 DogfreeModsWeekly Announcement Post

Hey Dogfree!
We just wanted to take this time to remind you of a few things if you haven't seen them already.
​
Related subs:
DogfreeHumor - For memes, comics, and other fun.
DogfreeAww - For aww minus the dogs.
DogfreeDating - Find a dogfree love.
DogcultureFree - For those who don't hate dogs but do hate dog culture.
BanPitBulls - For anything anti-pitbull. Please note that BanPitBulls is NOT anti-dog.
Petfree - For anyone who is annoyed with pets.
TalesfromtheDogHouse - For those wishing to vent about a specific dog and its behavior.
​
​
Previous Mod Statements:
The Definition of Dogfree - Dogfree is for those of us who do not like dogs.
Cats are Off Topic - This is not a cat subreddit. Cats are off topic.
Other Pets and Children are Off Topic - Other pets, children, and childbearing preferences are off topic.
Keeping Conversations Civil - Please be civil toward others. If someone is not being civil, please report them.
Letting Dogs Loose is Against the Rules -Don't suggest letting a dog escape.
Mindfulness Outside the Sub - Please be respectful of other subreddits and Reddit users.
Low Effort Content - What it is and how to post about things that fall in this category.
FAQ - Please check if your question can be answered here before posting.
​
Contact the Moderators of Dogfree - Please do not contact individual moderators directly about subreddit business including this account, DogfreeMods.
  • dogfree is its own forum that is not affiliated with any other website or platform, such as YouTube channels, social media pages, merchandise outlets, Discord servers, or other subreddits
submitted byDogfreeModstoDogfree [link][comments]

2021.11.24 22:08 PlayPUBGMobilePUBG MOBILE - Feast Of Legends - Full Rules

PUBG MOBILE CONTEST OFFICIAL RULES
  1. No Purchase Necessary; Entry Instructions. No purchase or payment of any money is necessary to enter. A purchase will not improve the chances of winning.
ODDS OF WINNING WILL DEPEND ON THE TOTAL NUMBER OF ELIGIBLE ENTRIES RECEIVED AND ON THE SKILL OF THE ENTRANT. VOID WHERE PROHIBITED BY LAW OR WHERE REGISTRATION, BONDING OR LOCALIZATION REQUIRED. SUBJECT TO ALL NATIONAL, REGIONAL AND LOCAL LAWS.
The participation rules for this Contest (“PUBG MOBILE Feast of Legends Challenge”) are available at the page which linked to these Official Rules (https://www.reddit.com/PUBGMobile/comments/r1cm58/pubg_mobile_feast_of_legends_community_event/) By posting or submitting an Entry, you are accepting the rules on the Promotion, these Official Rules and the Sponsor’s Terms of Service available at. Time and eligibility of Entry will be determined by Sponsor in its sole discretion. Sponsor will announce the winner through Facebook, Twitter, Twitch or any other social media channel (collectively, “Social Media Channels”) by which the participant participated or by other means consistent with the Promotion. All Entries must meet the following criteria:
· Entries must be original and not violate any third-party rights, and the entrant must have all rights necessary to submit the Entry.
· Entries may not contain material that is obscene, defamatory, libelous, threatening, pornographic, racially or ethnically offensive, or encourages conduct that would be considered a criminal offense, give rise to civil liability, or violate any law. Entries must be appropriate for viewing by the general public; appropriateness will be determined by Sponsor.
In the event of a dispute as to any entrant, the authorized holder of the associated account, email address or user name will be deemed to be the entrant. The “authorized holder” is the natural person assigned an account, email address or user name by an Internet access provider, online service provider, Social Media Channel or other organization responsible for assigning accounts, email addresses or user names. Each potential winner may be required to show proof of being the authorized holder. Sponsor will make final determination of identity of participants and timing of entries in its sole discretion.
  1. Eligibility. Entrants must be 13 years of age or older at the time of entry. Employees, officers and directors of this Promotion's hosting company, and each of their respective parents, affiliated companies and subsidiary companies, and their advertising, promotion, or production agencies, prize providers, Web masters and Web suppliers, and each of their respective officers, directors, employees, representatives and agents (collectively, with Sponsor, the “Promotion Entities”), and their IRS dependents, immediate families (spouse and parent, child, sibling and their respective spouses, regardless of where they reside) and/or members of their households, whether or not related, are ineligible to participate in this Promotion. By participating, entrants agree to these Official Rules and the decisions of the Sponsor, which are final and binding in all matters related to this Promotion. .
  2. Prizes. The Prizes for winning the promotion are as indicated on the Promotion Page. The prize(s) will be subject to the terms of the issuer. No substitution, assignment or transfer of the prize(s) is permitted, except by Sponsor, who has the right to substitute a prize with another of comparable or greater value. TAXES AND ANY OTHER COSTS, IF ANY, RELATED TO THE PRIZE ARE THE RESPONSIBILITY OF THE WINNER.
  3. Winner(s). Sponsor will select the number of winners as indicated on the Promotion Page. The winner(s) of the Promotion will be determined based on demonstrated skill in the area specified on the Promotion Page. Judging will be done by Sponsor or its designees.
In the event a potential winner is disqualified, the prize will be given to the next entrant eligible to win a prize based on the judging criteria. The winner will be attempted to be notified via their supplied contact information and will have fourteen (14) days from notification to accept the prize. Sponsor is not responsible for any delay or failure to receive notification for any reason, including inactive account(s), technical difficulties associated therewith, or winner’s failure to adequately monitor any account. Except where prohibited by law, participation in the Promotion constitutes participant’s consent to Sponsor’s use of participant’s Entry, name, likeness, voice, opinions, biographical information, and residence for promotional purposes in any media without further payment or consideration. Winner (and winner’s guest, if applicable) may be required to sign an affidavit of eligibility, liability release and a publicity release that, among other things, will further allow Sponsor to use a winner’s name, likeness, voice, opinions, biographical information, and residence for publicity and promotional purposes without further compensation where permitted by law.
  1. Conditions of Participation. By submitting an Entry for this Promotion, you agree to abide by these Official Rules and any decision Sponsor makes regarding this Promotion, which Sponsor or its designees shall make in their sole discretion. Sponsor reserves the right to disqualify and prosecute to the fullest extent permitted by law any participant or winner who, in Sponsor’s reasonable suspicion, tampers with Sponsor’s site, the entry process, intentionally submits more than the allowed entries, violates the Promotion Page terms or these Official Rules, or acts in an unsportsmanlike or disruptive manner.
  2. Intellectual Property: Ownership of the pre-existing underlying intellectual property of the entrant remains the property of the entrant subject to Sponsor’s rights to reprint, display, reproduce, perform, use, and exhibit the Entry for the purpose of administering and promoting the Promotion and for Sponsor’s marketing and advertising purposes, including on Sponsor’s website. By participating in the Promotion, each entrant grants to Sponsor a non-exclusive, worldwide, fully paid, royalty-free, perpetual, transferable license to reprint, display, reproduce, perform, use, and exhibit (including the right to make derivative works of) the Entry and materials and information submitted on and in connection with the Promotion or use or receipt of the prize for any and all purposes in any medium. Each participating entrant hereby warrants that any Entry and other materials and information provided by entrant are original with entrant and do not violate or infringe upon the copyrights, trademarks, rights of privacy, publicity or other intellectual property or other rights of any person or entity, and do not violate any rules or regulations. If the Entry or information or materials provided by entrant contain any material or elements that are not owned by entrant and/or which are subject to the rights of third parties, entrant represents he or she has obtained, prior to submission of the Entry and information or materials, any and all releases and consents necessary to permit use and exploitation of the Entry and information and materials by Sponsor in the manner set forth in the Official Rules without additional compensation.

Dating Sites For Usa

Each entrant warrants that the Entry and materials and information provided do not contain information considered by entrant, its employees or personnel, or any other third party to be confidential, and that the Entry, materials and information provided do not violate any laws or regulations. Entrant represents and warrants that he or she has permission from his employer or school and any necessary third party to enter the Promotion, take and submit Entry, and receive the prize. Entrant agrees that Sponsor has the right to verify the ownership and originality of all Entries and that, upon Sponsor’s request, entrant must submit a written copy of any release or permission entrant has received from a third party granting entrant the right to use such property. Entrant understands and acknowledges that in the event a submission is selected as a winning Entry, and entrant’s ownership, rights and the originality of the Entry cannot be verified to the satisfaction of Sponsor or is in any other way ineligible, Sponsor may select an alternate winner based on the same judging criteria.

Lists Of 100% Daily Online Dating Site In Usa Free


  1. Disclaimer, Release and Limit of Liability. SPONSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, REGARDING ANY PRIZE OR YOUR PARTICIPATION IN THE PROMOTION. BY ENTERING THE PROMOTION OR RECEIPT OF ANY PRIZE, EACH ENTRANT AGREES TO RELEASE AND HOLD HARMLESS SPONSOR, ANY THIRD-PARTY SOCIAL MEDIA CHANNELS UTILIZED FOR THE PROMOTION, AND THEIR SUBSIDIARIES, AFFILIATES, SUPPLIERS, DISTRIBUTORS, ADVERTISING/PROMOTION AGENCIES, AND PRIZE SUPPLIERS, AND EACH OF THEIR RESPECTIVE PARENT COMPANIES AND EACH SUCH COMPANY’S OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS (COLLECTIVELY, THE “RELEASED PARTIES”) FROM AND AGAINST ANY CLAIM OR CAUSE OF ACTION, INCLUDING, BUT NOT LIMITED TO, PERSONAL INJURY, DEATH, OR DAMAGE TO OR LOSS OF PROPERTY, ARISING OUT OF PARTICIPATION IN THE PROMOTION OR RECEIPT OR USE OR MISUSE OF ANY PRIZE. THE RELEASED PARTIES ARE NOT RESPONSIBLE FOR: (1) ANY INCORRECT OR INACCURATE INFORMATION, WHETHER CAUSED BY ENTRANTS, PRINTING ERRORS OR BY ANY OF THE EQUIPMENT OR PROGRAMMING ASSOCIATED WITH OR UTILIZED IN THE PROMOTION; (2) TECHNICAL FAILURES OF ANY KIND, INCLUDING, BUT NOT LIMITED TO MALFUNCTIONS, INTERRUPTIONS, OR DISCONNECTIONS IN PHONE LINES OR NETWORK HARDWARE OR SOFTWARE; (3) UNAUTHORIZED HUMAN INTERVENTION IN ANY PART OF THE ENTRY PROCESS OR THE PROMOTION; (4) TECHNICAL OR HUMAN ERROR WHICH MAY OCCUR IN THE ADMINISTRATION OF THE PROMOTION OR THE PROCESSING OF ENTRIES; OR (5) ANY INJURY OR DAMAGE TO PERSONS OR PROPERTY WHICH MAY BE CAUSED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, FROM ENTRANT’S PARTICIPATION IN THE PROMOTION OR RECEIPT OR USE OR MISUSE OF ANY PRIZE. If for any reason an entrant's Entry is confirmed to have been erroneously deleted, lost, or otherwise destroyed or corrupted, entrant’s sole remedy is another entry in the Promotion, provided that if it is not possible to award another entry due to discontinuance of the Promotion, or any part of it, for any reason, Sponsor, at its discretion, may elect to hold a random drawing from among all eligible entries received up to the date of discontinuance for any or all of the prizes offered herein. No more than the stated number of prizes will be awarded. In event that production, technical, programming or any other reasons cause more than stated number of prizes as set forth in these Official Rules to be available and/or claimed Sponsor reserves the right to award only the stated number of prizes by a random drawing among all legitimate, unawarded, eligible prize claims.
  2. Governing Law. These official rules and the promotion are governed by, and will be construed in accordance with, the laws of the state of California and of the United States of America and the forum and venue for any dispute arising out of or relating to these official rules shall be in San Jose, California. If the controversy or claim is not otherwise resolved through direct discussions or mediation, it shall then be resolved by final and binding arbitration administered by judicial arbitration and mediation services, Inc., in accordance with its streamlined arbitration rules and procedures or subsequent versions thereof (“JAMS rules”). The JAMS rules for selection of an arbitrator shall be followed, except that the arbitrator shall be experienced and licensed to practice law in the state of California. Any such controversy or claim will be arbitrated on an individual basis, and will not be consolidated in any arbitration with any claim or controversy of any other party. All proceedings brought pursuant to this paragraph will be conducted in San Jose, California. The remedy for any claim shall be limited to actual damages, and in no event shall any party be entitled to recover punitive, exemplary, consequential, or incidental damages, including attorney’s fees or other such related costs of bringing a claim, or to rescind this agreement or seek injunctive or any other equitable relief.
  3. Entrant's Personal Information. Information collected from entrants is subject to the Sponsor’s Privacy Policy, which is available at https://www.pubgmobile.com/privacy.html.
  4. Winner(s) List. Individuals may request the name of the winners by emailing (email) , within 90 days from the end of the Promotion period.
  5. Sponsor. Sponsor of this Promotion is Proxima Beta Pte Limited.
  6. No Affiliation with Social Media Channels. This Promotion is in no way sponsored, endorsed or administered by, or associated with, the Social Media Channels. You understand that you are providing your information to Sponsor and not to the Social Media Channels. The information you provide will only be used as described in these Official Rules and Sponsor’s privacy policy.
submitted byPlayPUBGMobiletoPUBGMobile [link][comments]

2021.11.24 21:30 michaelrama[FOR HIRE] Sales Letters So Sexy You'll Want To SPANK Them (With Money!): SELL MORE PRODUCTS & SERVICES With High Conversion Copy

Link to full offer 'MILLIONAIRE MAKER' Copywriter At Bargain Bin Prices... For A LIMITED Time Only:
'Highly Persuasive Sales Copy For Discerning Marketers...'
Flood your business with new customers with my battle-tested 'secret sauce' copywriting methods... I'll create persuasive new sales material for your business... reduce your ad spend... get more customers, and actually make a 'return on investment' with my affordable copywriting services.
Not the cheapest, but by far the most SUPERIOR copywriting service available here (and not as expensive as you may think)... there's plenty of services on offer. But do they have the skills to transform your WSO, service, or product into an irresistible offer that customers feel they must buy? More info below.
It converts, or I'll rewrite it free GUARANTEE (even though this has NEVER happened before)... myself and every copywriter I hire goes through rigorous training to ensure they can create sizzling high conversion sales copy with teeth... and powerful enough to compete in the dating, forex/crypto, weight loss, self improvement, and golf niches (the toughest niches to profit from... let alone ROAR with sales).
Dear fellow marketer,
Are you looking for 'battle tested' copywriting talent to sell significantly more products or services?
If so, you're in the right place.
Let me explain:
My name Is Joe Cassius...
And I've been a high-level underground copywriter for the past 8 years.
... and over the past 8 years, I've worked alongside some of the top online copywriters and marketing professionals...
And watched as they meticulously crafted 'wallet snatching' sales copy...
... making themselves and clients obscene amounts of money that I just can't disclose here.
In fact, if you're deep in the marketing game, chances are you've seen my sales copy used by professionals the world over... Some big names include Ewen Chia, Dean Jackson, & Ray Edwards... (plenty more, but I cannot reveal them to protect client interests).
Listen...
If you don't know who they are, don't worry about it.
All you need to know is that I'm about to make one of the CRAZIEST offers in the Warrior Forum 'services' category...
How?
I'll explain more in a sec, but just imagine this:
You wake up tomorrow morning, no pressure to be at work on time...
... no irritating traffic jams to sit through...
... no boss to look over your shoulder...
... in fact, you have complete freedom to roll out of bed when you feel like it... An 'alarm clock' becomes a thing of the past... You crack open your laptop, and wade through the dozens of 'notification of payment received' emails ...
... making $100's, maybe $1000's of dollars, without even lifting a finger.
The absolute best part about it?
Once you have just 1 profitable campaign...
It doesn't take much effort to 'leverage' it into even bigger profits...
... you're free to outsource time consuming tasks, work on things you want (if you feel like it)... and ultimately: Get filthy rich from your internet marketing empire... That's why trying to 'go it alone' can quickly end up frustrating you to the point of wanting to give up.
And if you've tried your best to create your own copy...
It's almost certain you've come across these common problems: Making your offer stand out amongst hundreds of competitors isn't easy... you could easily throw away weeks crafting, tweaking, testing small things on your own letter, but unless you're extremely lucky... it won't make the impact you were hoping for. People NOW more than ever are distracted by their Facebook, Instagrams, Youtube, whatever... the point is, cutting through the BS is crucial – and a 'mediocre' marketing message is NOT going to get through to your 'average Joe' ; unless it is extraordinary, or at least seems that way.
Most importantly... time is of the essence... do you have the time or patience to go through dozens of copywriting books... from authors like Eugene Schwartz, Gary Halbert, Vic Schwab, John Caples... all the way to 'newer' school writers like John Carlton and Michael Fortin... and then even newer copywriters like Ben Settle...
Reading their books, listening to their programs, and watching their seminars could take weeks...
But understanding them takes months...
Not to mention YEARS of effort required to actually hone those skills to a high level...
Basically, what I'm trying to say is this:
Time is money!
And if you're slaving away trying to figure out why your copy doesn't work...
Or all around getting poor results...
It's time to let a professional take over.
... Because in the end, you'll end up saving time, money, and frustration...
And sales that would otherwise have been lost due to a poorly written sales letter...
... suddenly become the 'life savers' you need to reach your financial goals.
In other words...
Hiring a professional from the get-go means you'll have... More sales, more money in the bank, and ultimately more FREEDOM to do the things you want...
Most people think using brute force or 'tricking' people with...
... fake scarcity...
... overly hyping up their products...
... making impossible ridiculous claims...
And more, is the only way to sell...
But this is the 'fake' copywriting I've been railing against for years.
At the very least, they serve as 'red flags' to avoid hiring complete amateurs.
Pro copywriters, on the other hand make your offer sound enticing, so people WANT to buy.
... without the gimmicks and tricks.
That's why hiring a professional is not a 'cost', but an 'investment'...
Because you'll end up making your money back many times over.
But ultimately, it's about your bottom line.
Just about anyone can 'say' they're a copywriter.
But very few have the 'real world' skills to produce consistent, profitable results...
And that's what I'm offering here...
Results.
And if you don't have $1000's to invest in professional copywriting services just yet...
And that's OK.
Because in a moment you'll discover how (and why), I'm going to offer you the same, high level copywriting skills you need for a mere FRACTION of the cost.
But you're probably asking yourself:
If I'm so good at copywriting...
... why am I about to make this 'ridiculous offer' in the first place? (fyi: this is NOT a made-up story like 99% of them out there.)
The truth is, COVID-19 destroyed a lot of livelihoods for many people I know.
And if you've seen or heard the news about Australia...
... then you know things are pretty bad down here.
And this is an opportunity to make some extra money in order to save some friends from losing their homes, livelihoods, and possibly even lives (sad but true... and most people will not tell you when they're at this stage).
But I digress...
I am very fortunate to have had the opportunity to learn and grow from the WF for many years now.
I used to spend hours on here every single day, learning everything about copywriting, SEO, paid traffic, affiliate marketing, and more...
Once I started having success, I slowly drifted away into the wider community, and honed my skills relentlessly.
After seeing how the multi-millionaires really do it...
... I finally 'graduated' to creating sales copy for my own products and services.
After all...
What's the point of spending 20-40+ hours creating insane high-powered sales copy, when I could just write for myself?
But like I said, this is not for me.
This is an EXTREMELY limited time offer to help people I care about...
... and in return, give YOU something of true value at a substantial discount rate (as a 'thank you' for helping me, to help my friends and family).
Anyway, you're probably wondering about the kind of results you can expect... Take this letter as a 'self-evident', compelling piece of copy. It's exactly why you're still reading right now...
And it just gives you a small taste of persuasive power your own sales letter will have.
But words are just words, right?
It means nothing without actual results...
https://www.warriorforum.com/warrior-special-offers/1442206-sales-letters-so-sexy-youll-want-spank-them-money-limited-time-offer-huge-discount.html
submitted bymichaelramatoforhire [link][comments]

Italian Singles, Chat, Dating, Italian Men & Women

  1. Rick Astley - Never Gonna Give You Up (Official Music ...
  2. Results - YouTube
  3. timeanddate - YouTube

The timeanddate.com YouTube channel mainly features streams of solar and lunar eclipses. Be sure to tune in for total lunar eclipses aka Blood Moons and total solar eclipses. Check out our site ... The official video for “Never Gonna Give You Up” by Rick Astley “Never Gonna Give You Up” was a global smash on its release in July 1987, topping the charts ... We would like to show you a description here but the site won’t allow us.

[ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] [ 6 ] [ 7 ] [ 8 ] [ 9 ] [ 10 ]